,REPORTED_TERM,DESC_CODED,LLT_NAME_COMPL,PT_NAME_COMPL,HLT_NAME_COMPL,HLGT_NAME_COMPL,SOC_CODE,INC_CODE_J,ART_CODE,INC_CODE
100,AZITHROMYCIN AND CEFTRIAXONE FOR THE TREATMENT OF PLEURAL EFFUSION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
121,PATIENT WAS TREATED WITH TERBINAFINE FOR FUSARIUM SOLANI KERATITIS,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
167,FENTANYL USE FOR PELVIC PAIN DUE TO INTERSTITIAL CYSTITIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
204,URETERAL STONES,Ureterolithiasis,URETEROLITHIASIS,URETEROLITHIASIS,URINARY TRACT LITHIASIS (EXCL RENAL),UROLITHIASES,10038359,10077989,10077989,10077989
223,LIVER FUNCTION TEST INCREASED,Liver function test increased,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10077692
270,NOT ABLE TO PERFORM ORDINARY GESTURES,Activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
339,SEPTIC SHOCK WITH MULTIORGAN FAILURE,multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
448,MALIGNANT CATATONIA,Malignant catatonia,MALIGNANT CATATONIA,MALIGNANT CATATONIA,DECREASED PHYSICAL ACTIVITY LEVELS,CHANGES IN PHYSICAL ACTIVITY,10037175,10080149,10080149,10080149
457,CETIRIZINE HYDROCHLORIDE USED FOR PRURITUS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
488,HYDROXYCHLOROQUINE SULFATE USED FOR TREATMENT OF PULMONARY HEMOSIDEROSIS WITH NO ADVERSE EVENT,hydroxychloroquine sulfate used for treatment of pulmonary hemosiderosis with no adverse event,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
551,INSUFFICIENT RESPONSE TO PREDNISOLONE AND RITUXIMAB,Partial responder to therapy,PARTIAL RESPONDER TO THERAPY,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10066429,10078115,10066429
633,NORMOCYTIC ANEMIA,normocytic anemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029785,10029784,10029785
673,DRUG USE FOR UNAPPROVED INDICATION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
702,SELFLIMITING DIARRHEA PROBABLY DUE TO EXPOSURE TO SERTRALINE IN BREAST MILK,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
745,HEMORRHAGIC PNEUMONIA WITH HYPOXIA,Haemorrhagic pneumonia,HEMORRHAGIC PNEUMONIA,HAEMORRHAGIC PNEUMONIA,LOWER RESPIRATORY TRACT AND LUNG INFECTIONS,INFECTIONS - PATHOGEN UNSPECIFIED,10021881,10077933,10077933,10077935
771,CARDIAC FUNCTION DETERIORATION,Cardiac dysfunction,CARDIAC DYSFUNCTION,CARDIAC DYSFUNCTION,CARDIAC DISORDERS NEC,CARDIAC DISORDER SIGNS AND SYMPTOMS,10007541,10079751,10079751,10079751
864,DRUG EXPOSURE DURING BREAST FEEDING,Drug exposure via breast milk ,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
996,MULTIPLE ORGAN DYSFUNCTION,Multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
1007,VACCINE CONTRAINDICATED FOR USE IN SCID PATIENTS,Contraindicated drug prescribed,CONTRAINDICATED DRUG PRESCRIBED,CONTRAINDICATED DRUG PRESCRIBED,PRODUCT PRESCRIBING ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10078779,10078779,10078779
1010,OESOPHAGEAL SUBMUCOSAL HAEMATOMA,Oesophageal intramural haematoma,OESOPHAGEAL INTRAMURAL HAEMATOMA,OESOPHAGEAL INTRAMURAL HAEMATOMA,GASTRIC AND OESOPHAGEAL HAEMORRHAGES,GASTROINTESTINAL HAEMORRHAGES NEC,10017947,10077486,10077486,10077486
1032,LATE HYPOXIC CARDIAC ARREST SECONDARY TO CRITICAL ILLNESS POLYNEUROMYOPATHY,critical illness polyneuromyopathy,CRITICAL ILLNESS POLYNEUROMYOPATHY,INTENSIVE CARE UNIT ACQUIRED WEAKNESS,ACUTE POLYNEUROPATHIES,PERIPHERAL NEUROPATHIES,10029205,10078315,10077255,10078315
1043,DRUG CROSS-REACTIVITY,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
1111,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
1150,HIV-1 PERSISTENT VIREMIA FOLLOWING EFAVIRENZ RESISTANCE,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
1172,FINALLY. IN COMPLETE CESSATION ON THE FIFTH DAY,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
1197,PERIORAL FURROWING,Dermatitis perioral,DERMATITIS PERIORAL,PERIORAL DERMATITIS,DERMATITIS AND ECZEMA,EPIDERMAL AND DERMAL CONDITIONS,10040785,10012484,10034541,10012484
1227,"BLUE-GRAY PIGMENTATION ON POSTERIOR AXILLARY FOLDS, ORAL MUCOSA AND HARD PALATE",palatal pigmentation,PALATAL PIGMENTATION,ORAL PIGMENTATION,ORAL SOFT TISSUE SIGNS AND SYMPTOMS,ORAL SOFT TISSUE CONDITIONS,10017947,10077553,10077552,10077553
1267,OUR TEAM MADE A PLAN TO START A TRIAL OF LOW-DOSE LEVODOPA-CARBIDOPA FOR IMPROVEMENT OF HER MOVEMENT DISORDER,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1274,PREDNISONE USED IN KIDNEY TRANSPLANT,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
1283,MULTIORGAN FAILURE FOLLOWING WORSENING OF KLEBSIELLA PNEUMONIAE INFECTION,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
1295,ARIPIPRAZOLE AND RISPERIDONE USED FOR TREATMENT OF DISORDER INTERFERING WITH DEVELOPMENT,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1306,GAMBLING ADDICTION/COMPULSION FOR GAMBLING,Gambling disorder,GAMBLING ADDICTION,GAMBLING DISORDER,SUBSTANCE RELATED AND ADDICTIVE DISORDERS,PSYCHIATRIC DISORDERS NEC,10037175,10017656,10078070,10017656
1359,IMATINIB FOR SLERODERMATOUS CGVHD,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1400,"SINCE EXAMS DEMONSTRATED NORMAL HEPATIC FUNCTION, ORAL TREATMENT WAS ALTERED TO TERBINAFINE WITH IMPROVEMENT AFTER 8 WEEKS.",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1469,CHRONIC GRANULOMATOUS INFLAMMATION IN AORTIC WALL AND LYMPH NODES,granulomatous inflammation,GRANULOMATOUS LYMPHADENITIS,GRANULOMATOUS LYMPHADENITIS,LYMPHATIC SYSTEM DISORDERS NEC,"SPLEEN, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEM DISORDERS",10005329,10078494,10078494,10078494
1471,SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
1534,MULTIPLE ORGAN FAILURE,Multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
1560,MUCOSAL FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
1580,SLEEP DISRUPTION,Non-24-hour sleep-wake disorder,DISRUPTIONS OF 24 HOUR SLEEP-WAKE CYCLE,NON-24-HOUR SLEEP-WAKE DISORDER,DISTURBANCES IN SLEEP PHASE RHYTHM,SLEEP DISTURBANCES (INCL SUBTYPES),10029205,10013419,10078086,10013419
1586,PATIENT WAS UNRESPONSIVE TO BETAMETHASONE VALERATE,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
1780,HIGH- DOSE PIRACETAM IS EFFECTIVE ON CEREBELLAR ATAXIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1790,ASPIRIN AND CLOPIDOGREL USED FOR TRANSIENT ISCHEMIC ATTACK,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1834,THERAPY NON-RESPONDER,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
1885,HE MET CRITERIA FOR KD AND RECEIVED IVIG AND ASPIRIN,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1886,PATERNAL EXPOSURE BEFORE PREGNANCY,Paternal exposure before pregnancy,PATERNAL EXPOSURE BEFORE PREGNANCY,PATERNAL EXPOSURE BEFORE PREGNANCY,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080093,10080093,10080093
1911,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
1978,MILD DYSMETRIA DUE TO DRUG INTERACTION,dysmetria,DYSMETRIA,DYSMETRIA,COORDINATION AND BALANCE DISTURBANCES,NEUROLOGICAL DISORDERS NEC,10029205,10013936,10013936,10013936
2038,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
2117,LIMBIC ENCEPHALITIS,Limbic encephalitis,LIMBIC ENCEPHALITIS,LIMBIC ENCEPHALITIS,ENCEPHALITIS NEC,CENTRAL NERVOUS SYSTEM INFECTIONS AND INFLAMMATIONS,10029205,10078012,10078012,10078012
2242,PRODUCT USE IN UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
2253,HYPERLEUKOCYTOSIS PROGRESSION,Hyperleukocytosis,HYPERLEUKOCYTOSIS,HYPERLEUKOCYTOSIS,LEUKOCYTOSES NEC,WHITE BLOOD CELL DISORDERS,10005329,10078862,10078862,10078862
2269,APPARENT MINERALOCORTICOID EXCESS,Apparent mineralocorticoid excess,APPARENT MINERALOCORTICOID EXCESS,APPARENT MINERALOCORTICOID EXCESS,ENDOCRINE DISORDERS CONGENITAL NEC,ENDOCRINE DISORDERS CONGENITAL,10010331,10080229,10080229,10080229
2323,TREATMENT WITH TRADITIONAL NEURO-STIMULANTS RESULTED IN MINIMAL CHANGE. HE WAS STARTED ON ZOLPIDEM 3 MONTHS AFTER INJURY.,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
2324,DRUG CROSS-REACTIVITY,Therapeutic product cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
2406,"HEPARIN (TARGET APTT 1.5 TIMES) AND WARFARIN (TARGET INR 2-3) WERE USED IN COMBINATION; HOWEVER, SINCE THE THROMBUS INCREASED",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
2433,"INFLAMMATORY CELL INFILTRATION AROUND MUSCLE FIBER, AND MINIMAL CELL INFILTRATION IN MUSCLE FIBER. NEUTROPHILS WERE PREDOMINANT CELL TYPE(PERIMYSIAL AND ENDOMYSIAL INFILTRATION OF NEUTROPHILS)",Tissue infiltration,TISSUE INFILTRATION,TISSUE INFILTRATION,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10080901,10080901,10080901
2443,PATIENT RECEIVED SUCCESSFUL TREATMENT WITH GABAPENTIN AND PREGABALIN FOR CHRONIC FATIGUE,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
2596,ATYPICAL HEMOLYTIC UREMIC SYNDROME FOLLOWING RENAL FAILURE,atypical hemolytic uremic syndrome,ATYPICAL HEMOLYTIC UREMIC SYNDROME,ATYPICAL HAEMOLYTIC URAEMIC SYNDROME,ANAEMIAS HAEMOLYTIC MECHANICAL FACTOR,HAEMOLYSES AND RELATED CONDITIONS,10005329,10079841,10079840,10079841
2601,WAS ALTERED TO TERBINAFINE WITH IMPROVEMENT AFTER 8 WEEKS.,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
2700,DILATATION OF RIGHT VENTRICLE DUE TO PULMONARY HYPERTENSION,Right ventricular dilatation,RIGHT VENTRICULAR DILATATION,RIGHT VENTRICULAR DILATATION,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10074222,10074222,10074222
2777,MYCOPHENOLATE MOFETIL USED FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
2809,CONTROL OF SPASMS AND DYSAUTONOMIA WAS VERY DIFFICULT IN THE FIRST PATIENT EVEN FOLLOWING PHENOBARBITONE AND THIOPENTAL,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
2815,CONTRAINDICATED DRUG ADMINISTERED,Contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
2827,TRANSDERMAL PATCH AND MINIPILL PRESCRIBED FOR CYCLIC IRREGULARITY,transdermal patch and minipill prescribed for cyclic irregularity,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
2830,METHOTREXATE WAS USED FOR GVHD PROPHYLAXIS (DRUG USED FOR UNAPPROVED INDICATION),drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
2842,CROSS-REACTION TO DEXAMETHASONE AND SOLU-DECORTIN H,Therapeutic product cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
2870,GROWTH VELOCITY OF THE GIRL SHOWED A BREAK WHEN SHE STARTED IMATINIB,Growth failure,GROWTH FAILURE,GROWTH FAILURE,MUSCULOSKELETAL AND CONNECTIVE TISSUE CONDITIONS NEC,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS NEC,10028395,10071095,10071095,10071095
2922,HIV VIREMIA,HIV viremia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077718,10077716,10077718
2958,DIED OF HYPODYNAMIC SEPTIC SHOCK REFRACTORY TO THE TREATMENT (LINEZOLID),Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
2975,MULTI ORGAN FAILURE,multi organ failure,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028151,10077361,10028151
3015,MULTIORGAN FAILURE FOLLOWING POST-LT MYCOTIC ANEURYSM OF THE HEPATIC ARTERY,multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
3025,MULTI ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
3075,"FLARE UP  OF ADULT ONSET STILL'S DISEASE DUE TO LACK OF DRUG EFFECT OF PREDNISOLONE, METHYLPREDNISOLONE AND AZATHIOPRINE",Still's disease adult onset,STILL'S DISEASE ADULT ONSET,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10064056,10042061,10064056
3176,GRADE II ISCHAEMIC MITRAL REGURGITATION,ischaemic mitral regurgitation,ISCHAEMIC MITRAL REGURGITATION,ISCHAEMIC MITRAL REGURGITATION,MITRAL VALVULAR DISORDERS,CARDIAC VALVE DISORDERS,10007541,10077864,10077864,10077864
3178,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
3273,MULTIORGAN FAILURE DUE TO SEPTIC SHOCK FOLLOWING SEPSIS,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
3294,MINOCYCLINE-INDUCED PSEUDOTUMOR CEREBRI,Idiopathic intracranial hypertension,PSEUDOTUMOR CEREBRI,IDIOPATHIC INTRACRANIAL HYPERTENSION,INCREASED INTRACRANIAL PRESSURE DISORDERS,INCREASED INTRACRANIAL PRESSURE AND HYDROCEPHALUS,10029205,10073807,10078904,10037149
3321,RELAPSE OF ADULT ONSET STILL'S DISEASE FOLLOWING REBOUND EFFECT OF PREDNISONE,Still's disease,ADULT ONSET STILL'S DISEASE,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10079456,10042061,10079456
3356,GREAT IMPROVEMENT OF STIFFNESS WITH FLECAINIDE,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
3382,MULTI ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
3386,IBUPROFEN AND NIMESULIDE USED FOR ANKYLOSING SPONDYLITIS,product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
3461,EXCESSIVE DAYTIME SEDATION,Sedation excessive,SEDATION EXCESSIVE,SEDATION COMPLICATION,ANAESTHETIC AND ALLIED PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10039898,10079741,10039898
3492,MULTI ORGAN FAILURE FOLLOWING SEPTIC SHOCK,Multi organ failure,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028151,10077361,10028151
3586,POSTPRANDIAL HYPOGLYCAEMIA,Postprandial hypoglycaemia,POSTPRANDIAL HYPOGLYCAEMIA,POSTPRANDIAL HYPOGLYCAEMIA,HYPOGLYCAEMIC CONDITIONS NEC,GLUCOSE METABOLISM DISORDERS (INCL DIABETES MELLITUS),10027433,10059035,10059035,10059035
3753,OLMESARTAN-ASSOCIATED ENTEROPATHY,sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
3783,PATIENT HAD NO BENEFIT/DRUG INEFFECTIVENESS/NO THERAPEUTIC RESPONSE,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
3821,PULMONARY MALAKOPLAKIA,Malacoplakia,MALACOPLAKIA,MALACOPLAKIA,INFLAMMATIONS,GENERAL SYSTEM DISORDERS NEC,10018065,10080344,10080344,10080344
3962,MULTIPLE-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
4056,INABILITY TO WALK,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
4071,ACUTE FACIAL PARALYSIS,facial paralysis,FACIAL PARALYSIS,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016062
4168,PREDNISONE USED FOR DUCHENNE MUSCULAR DYSTROPHY,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
4217,DRUG CROSS-REACTIVITY,Therapeutic product cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
4277,"MYCOPHENOLATE MOFETIL, HYDROXYCHLOROQUINE AND CYCLOPHOSPHAMIDE USED FOR PULMONARY HEMOSIDEROSIS WITH NO ADR",Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
4298,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,Eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10078117,10078117,10078117
4302,MULTI ORGAN DYSFUNCTION,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
4324,BENDAMUSTINE USED FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
4414,EXACERBATION OF PLASMA CELL VULVITIS (ZOON'S VULVITIS),Plasma cell vulvitis,PLASMA CELL VULVITIS,PLASMA CELL VULVITIS,VAGINAL AND VULVAL INFECTIONS AND INFLAMMATIONS,FEMALE REPRODUCTIVE TRACT INFECTIONS AND INFLAMMATIONS,10038604,10079057,10079057,10079057
4436,FECAL INCONTINENCE,fecal incontinence,FECAL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10016296,10077605,10016296
4472,"THERAPY-RESISTANT MULTI-ORGAN FAILURE (RENAL DYSFUNCTION, LIVER DYSFUNCTION, PLATELET DYSFUCTION) FOLLOWING AGRANULOCYTOSIS",Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
4479,"SHE WAS INSTEAD GIVEN NAFTIDROFURYL OXALATE, AN ALTERNATIVE PERIPHERAL VASODILATOR USUALLY RESERVED FOR THE MANAGEMENT OF INTERMITTENT ARTERIAL CLAUDICATION IN PERIPHERAL VASCULAR DISEASE.",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
4588,MULTIVISCERAL FAILURES FOLLOWING WORSENING OF ACUTE GVHD-RELATED ENCEPHALITIS DESPITE TREATMENT WITH METHYLPREDNISOLONE,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
4593,PATIENT EXPERIENCED A PARTIAL AND NON PERMANENT PAIN CONTROL DURING THE THERAPY WITH ETORICOXIB TAKEN FOR THE TREATMENT OF SPONDYARTHROSIS WITH BILATERAL PAINFUL SHOULDER AND MULTIPLE DISC HERNIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
4609,THE LESIONS HAD NOT IMPROVED,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
4617,MULTIPLE ORGAN DYSFUNCTION DUE TO HEMORRHAGIC SHOCK FOLLOWING HENOCH-SCHONLEIN PURPURA,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
4686,OFF LABEL USE/FOR ACUTE IDIOPATHIC OPTIC NEURITIS,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
4709,NORMOCYTIC ANEMIA,Normocytic anaemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029785
4745,CYTOMEGALOVIRUS NEPHRITIS,Cytomegalovirus nephritis,CYTOMEGALOVIRUS NEPHRITIS,CYTOMEGALOVIRUS NEPHRITIS,CYTOMEGALOVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10079095,10079095,10079095
4853,DRUG CROSS-REACTIVITY,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
4985,ECHOGENIC BOWEL,fetal gastrointestinal tract imaging abnormal,FETAL GASTROINTESTINAL TRACT IMAGING ABNORMAL,FOETAL GASTROINTESTINAL TRACT IMAGING ABNORMAL,FOETAL AND NEONATAL IMAGING PROCEDURES,FOETAL AND NEONATAL INVESTIGATIONS,10022891,10077587,10077579,10077587
5135,HIV-1 PERSISTENT VIREMIA FOLLOWING DRUG RESISTANCE DUE TO V82AV MUTATION,HIV viremia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077718,10077716,10077718
5173,POST-CESARIAN OGILVIE SYNDROME,Ogilvie's syndrome,OGILVIE'S SYNDROME,INTESTINAL PSEUDO-OBSTRUCTION,GASTROINTESTINAL ATONIC AND HYPOMOTILITY DISORDERS NEC,GASTROINTESTINAL MOTILITY AND DEFAECATION CONDITIONS,10017947,10052504,10022698,10052504
5207,TRANSDERMAL PATCH AND MINIPILL PRESCRIBED FOR CYCLE IRREGULARITY,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5267,"BLUE LIGHT IN THE CENTRAL FIELD OF THE RIGHT EYE, PULSATING COINCIDENTLY WITH HIS HEARTBEAT","blue light in the central field of the right eye, pulsating coincidently with his heartbeat",COLOUR VISION CHANGE,DYSCHROMATOPSIA,COLOUR BLINDNESS (INCL ACQUIRED),VISION DISORDERS,10015919,10068918,10013892,10068918
5285,MULTI-ORGAN FAILURE FOLLOWING KLEBSIELLA PNEUMONIAE INFECTION,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
5310,TREATED WITH 600 MG FLUCONAZOLE TWICE DAILY,Product prescribing issue,INAPPROPRIATE PRESCRIBING,PRODUCT PRESCRIBING ISSUE,PRODUCT PRESCRIBING ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10079271,10080459,10079271
5352,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5359,PSYCHO-ORGANIC SYNDROME,Psychoorganic syndrome,PSYCHOORGANIC SYNDROME,ORGANIC BRAIN SYNDROME,MENTAL DISORDERS DUE TO A GENERAL MEDICAL CONDITION NEC,PSYCHIATRIC DISORDERS NEC,10037175,10078099,10031077,10078099
5376,ACTIVITIES OF DAILY LIVING IMPAIRED,Activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
5395,DRUG EXPOSURE VIA BREAST MILK WITH NO ADR,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
5505,TOOK DULOXETINE 90 MG DAILY AND METHYLPHENIDATE 36 MG DAILY DURING PREGNANCY AND BREAST FEEDING,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
5511,FLUCONASOLE USED FOR PRO-T-ALL,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5561,NO IMPROVEMENT,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
5591,MULTI-SYSTEM ORGAN FAILURE DUE TO PROGRESSION OF VIBRIO VULNIFICUS SEPTICEMIA,multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
5602,LACK OF RESPONSE TO ANTIFUNGAL TREATMENT FOR ASPERGILLUS INFECTION,no therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
5616,AMIODARONE-INDUCED VORTEX KERATOPATHY,Vortex keratopathy,VORTEX KERATOPATHY,CORNEA VERTICILLATA,"CORNEAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION","ANTERIOR EYE STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION",10015919,10077621,10077604,10077621
5656,PREDNISONE USED IN KIDNEY TRANSPLANTATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5663,EOSINOPHILIC PLEURAL EFFUSION/IATROGENIC PLEURAL EFFUSION DUE TO DRUG REACTION,Eosinophilic pleural effusion,EOSINOPHILIC PLEURAL EFFUSION,EOSINOPHILIC PLEURAL EFFUSION,PNEUMOTHORAX AND PLEURAL EFFUSIONS NEC,PLEURAL DISORDERS,10038738,10080148,10080148,10080148
5694,EPHEDRINE 20MG WAS ADMINISTERED WITHOUT IMPROVEMENT IN VITAL SIGNS,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
5758,RAMIPRIL USED FOR DILATED CARDIOMYOPATHY,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5824,ACUTE-ON-CHRONIC LIVER FAILURE DUE TO LIVER CIRRHOSIS,Acute on chronic liver failure,ACUTE ON CHRONIC LIVER FAILURE,ACUTE ON CHRONIC LIVER FAILURE,HEPATIC FAILURE AND ASSOCIATED DISORDERS,HEPATIC AND HEPATOBILIARY DISORDERS,10019805,10077305,10077305,10077305
5840,OLMESARTAN-INDUCED ENTEROCOLOPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
5851,"CONTINUED TO RECEIVE ASPIRIN, 100MG DAILY (DESPITE GASTRIC BLEEDING)",Contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
5865,MULTIORGAN FAILURE FOLLOWING SEPTIC SHOCK,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
5887,MYCOPHENOALTE MOFETIL USED OR SYMPTOMATIC AUTOIMMUNE HEPATITIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5904,WORSENING DYSTONIA REQUIRED INCREASE DOSE OF BACLOFEN & CLONIDINE,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5920,DULOXETINE USED FOR TREATMENT OF NEUROPATHIC PAIN,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5970,GABAPENTIN USED FOR ANALGESIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
5998,CITALOPRAM WITH MOCLOBEMID AND OF FLUOXETINE WITH MOCLOBEMIDE,Contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
6006,VORICONAZOLE USED FOR BULLOUS NECROTIC PURPURA,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
6035,EXACERBATED OF SEIZURES/NOVAL COMPLEX PARTIAL SEIZURES,complex partial seizures exacerbated,COMPLEX PARTIAL SEIZURES EXACERBATED,FOCAL DYSCOGNITIVE SEIZURES,PARTIAL COMPLEX SEIZURES,SEIZURES (INCL SUBTYPES),10029205,10010146,10079424,10010146
6110,ADVANCED EMPD THAT WERE SUCCESSFULLY CONTROLLED BY DOCETAXEL WITH CISPLATIN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
6120,PAINLESS GREY-BLUE WIDESPREAD HYPERPIGMENTATION OF THE HARD PALATE MUCOSA ASSOCIATED WITH IMATINIB,Oral pigmentation,PALATAL PIGMENTATION,ORAL PIGMENTATION,ORAL SOFT TISSUE SIGNS AND SYMPTOMS,ORAL SOFT TISSUE CONDITIONS,10017947,10077553,10077552,10077553
6129,ONGOING ARRHYTHMIA,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
6130,METHOTREXATE USED FOR AXIAL SPONDYLOARTHRITIS,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
6160,PATIENT RECEIVED RAMIPRIL FOR DIABETES,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
6190,DRUG CROSS-REACTIVITY WITH OMEPRAZOLE AND PANTOPRAZOLE,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
6220,FACIAL DROOP FOLLOWING PARADOXICAL DRUG REACTION,Facial paralysis,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016044
6252,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
6307,MULTI ORGAN FAILURE FOLLOWING SEPTIC SHOCK,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
6325,RITUXIMAB USED FOR MUCOUS MEMBRANE PEMPHIGOID,Rituximab used for mucous membrane pemphigoid,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
6350,SEVERE MULTIPLE ORGAN FAILURE FOLLOWING ASPERGILLUS TAMARII INFECTION,multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
6497,FAILED TO RESPOND TO SUCCESSIVE TREATMENTS,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
6573,DRUG EXPOSURE VIA LACTATION WITH NO ADR,Exposure via breast milk,EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080751,10080751,10080751
6775,FETAL TACHYARRHYTHMIA,foetal tachyarrhythmia,FOETAL TACHYARRHYTHMIA,FOETAL TACHYARRHYTHMIA,RATE AND RHYTHM DISORDERS NEC,CARDIAC ARRHYTHMIAS,10007541,10077575,10077575,10077575
6834,MODERATE SPRUE-LIKE ENTEROPATHY ASSOCIATED WITH TELMISARTAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
6840,HERPES SIMPLEX VIRUS SKIN POSITIVE,Herpes simplex test positive,HERPES SIMPLEX TEST POSITIVE,HERPES SIMPLEX TEST POSITIVE,VIRUS IDENTIFICATION AND SEROLOGY,MICROBIOLOGY AND SEROLOGY INVESTIGATIONS,10022891,10077969,10077969,10077969
6878,UNILATERAL  ISOLATED  UPPER  MOTOR NEURONE FACIAL NERVE PALSY,Facial paralysis,FACIAL PALSY,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016060,10016062,10016060
6913,MULTIORGAN DYSFUNCTION,Multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
7055,KETOSIS-PRONE DIABETES MELLITUS,Ketosis-prone diabetes mellitus,KETOSIS-PRONE DIABETES MELLITUS,KETOSIS-PRONE DIABETES MELLITUS,DIABETES MELLITUS (INCL SUBTYPES),GLUCOSE METABOLISM DISORDERS (INCL DIABETES MELLITUS),10027433,10023392,10023392,10023392
7107,SHE WAS TREATED WITH CARVEDILOL FOR ANEMIA SECONDARY TO PHG,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
7182,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
7257,ACETYLSALICYLIC ACID EXPOSURE DURING PREGNANCY DURING FIRST-TRIMESTER,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
7346,NONCIRRHOTIC PORTAL HYPERTENSION (NCPH),Non-cirrhotic portal hypertension,NON-CIRRHOTIC PORTAL HYPERTENSION,NON-CIRRHOTIC PORTAL HYPERTENSION,HEPATIC VASCULAR DISORDERS,HEPATIC AND HEPATOBILIARY DISORDERS,10019805,10077259,10077259,10077259
7350,"MULTI-ORGAN DYSFUNCTION PROGRESSED WITH CARDIOVASCULAR, LUNG, LIVER AND KIDNEY FOLLOWING DRUG INDUCED LONG QT SYNDROME SECONDARY TO TOXICITY FROM MEGLUMINE ANTIMONIATE",Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
7438,VINSCRISTINE AND VORINCONAZOLE WERE ADMINISTERED CONCURRENTLY (CONTRAINDICATED DRUG ADMINISTERED),contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
7475,DIFFUSE NEUROENDOCRINE HYPERPLASIA OF THE LUNG,Pulmonary nodular lymphoid hyperplasia,PULMONARY NODULAR LYMPHOID HYPERPLASIA,PULMONARY NODULAR LYMPHOID HYPERPLASIA,PARENCHYMAL LUNG DISORDERS NEC,LOWER RESPIRATORY TRACT DISORDERS (EXCL OBSTRUCTION AND INFECTION),10038738,10077412,10077412,10077412
7562,ASPIRIN USED IN PREGNANCY DURING THE LAST THREE MONTHS,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
7568,MULTIPLE ORGAN FAILURE FOLLOWING RENAL FUNCTION DETERIORATED AND DISTURBANCE OF CONSCIOUSNESS DUE TO LACK OF DRUG EFFECT,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
7667,LEFT FACIAL PALSY,Facial paralysis,FACIAL PARALYSIS,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016062
7693,EXAMINATION OF BUCCAL MUCOSAL SURFACES REVEALED SLIGHT HYPERPIGMENTATION WITHOUT EVIDENCE OF WICKHAM STRIAE,Oral pigmentation,PIGMENTATION BUCCAL,ORAL PIGMENTATION,ORAL SOFT TISSUE SIGNS AND SYMPTOMS,ORAL SOFT TISSUE CONDITIONS,10017947,10035020,10077552,10035020
7708,PREDNISOLONE USED FOR KIDNEY TRANSPLANT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
7711,SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
7740,FIXED DRUG ERUPTION DUE TO ALLYLISOPROPYLACETYLUREA,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
7758,DRUG USE FOR UNAPPROVED INDICATION (MTX FOR NECROTISING MYOSITIS),Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
7805,DRUG EXPOSURE VIA BREAST MILK WITH NO ADVERSE EVENT,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
7819,CURRENTLY SEVERE DEPRESSIVE EPISODE WITH PSYCHOTIC SYMPTOMS,currently severe depressive episode with psychotic symptoms,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
7835,CUTANEOUS PHAEOHYPHOMYCOSIS FOLLOWING PHAEOACREMONIUM INFECTION,Phaeohyphomycosis,PHAEOHYPHOMYCOSIS,PHAEOHYPHOMYCOSIS,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10080815,10080815,10080815
7866,MULTIORGAN FAILURE,multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
7869,MRI OF  THE  BRAIN DEMONSTRATED MASS LESIONS VERSUS ABSCESSES IN EACH HEMISPHERE AND THE LEFT CEREBELLAR PONTINE ANGLE,Intracranial mass,INTRACRANIAL MASS,INTRACRANIAL MASS,STRUCTURAL BRAIN DISORDERS NEC,STRUCTURAL BRAIN DISORDERS,10029205,10077667,10077667,10077667
7878,FACIAL NERVE PALSY,bell palsy,PALSY BELLS,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10033559,10016062,10033559
7955,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
7970,EXPERIENCED LITHIUM-INDUCED END STAGE RENAL DISEASE,End stage renal disease,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
8010,HIS LONG TERM MEDICATION CONSISTED OF IBUPROFEN 3 Ã— 800 MG PER DAY FOR CHRONIC PAIN,Product prescribing issue,INAPPROPRIATE PRESCRIBING,PRODUCT PRESCRIBING ISSUE,PRODUCT PRESCRIBING ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10079271,10080459,10079271
8067,CROSS-SENSITIVITY BETWEEN AMPILLIN AND CEFUROXIME,Therapeutic product cross-reactivity,CROSS SENSITIVITY REACTION,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10011411,10079645,10011411
8100,OLMESARTAN-INDUCED ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
8129,MULTI-ORGAN FAILURE,multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
8159,WOMAN WAS ADMINISTERED MULTIPLE DRUGS WHILE SHE WAS BREASTFEEDING THE CHILD (DRUG EXPOSURE VIA BREAST MILK) WITH NO ADVERSE EVENT,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
8208,REFRACTORY TO FLUDARABINE,Refractory to fludarabine,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
8245,SKIN LAXITY,skin laxity,SKIN LAXITY,SKIN LAXITY,DERMAL AND EPIDERMAL CONDITIONS NEC,EPIDERMAL AND DERMAL CONDITIONS,10040785,10057064,10057064,10057064
8331,THE PATIENT WAS ADMINISTERED ADENOSINE AND DILTIAZEM WITH NO RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
8690,PATIENT TREATED WITH FLUOROURACIL AND OXALIPLATIN FOR PANCREATIC DUCTAL CARCINOMA (DRUG USE FOR UNAPPROVED INDICATION),Drug use for unapproved indication ,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
8778,DRUG USE FOR UNAPPROVED INDICATION,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
8828,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS FLARED DUE TO REBOUND EFFECT OF PREDNISONE,Eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10078117,10078117,10078117
8842,MYCOPHENOLATE MOFETIL AND HYDROXYCHLOROQUINE USED FOR PULMONARY HEMOSIDEROSIS WITH NO REORTED ADR,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
8857,HYPOCHONDRIA,Illness anxiety disorder,HYPOCHONDRIACAL PERSONALITY,ILLNESS ANXIETY DISORDER,SOMATIC SYMPTOM DISORDERS,SOMATIC SYMPTOM AND RELATED DISORDERS,10037175,10020963,10078077,10020963
8924,MARKEDLY ELEVATED LIVER TESTS,Liver function test increased,LIVER FUNCTION TESTS RAISED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10048556
8942,NECROTIC ULLCERATIONS ON THE PALATE,palatal ulcer,PALATAL ULCER,PALATAL ULCER,STOMATITIS AND ULCERATION,ORAL SOFT TISSUE CONDITIONS,10017947,10077519,10077519,10077519
8951,OLMESARTAN-ASSOCIATED SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
8977,EXPOSURE OF CLINDAMYCIN AND GENTAMICIN VIA BREASTFEEDING,Maternal exposure during breast feeding,EXPOSURE DURING BREAST FEEDING,MATERNAL EXPOSURE DURING BREAST FEEDING,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10071402,10080752,10071402
9057,CYCLOPHOSPHAMIDE FOR THE TREATMENT OF SUSAC SYNDROME,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
9191,TAKING ABILIFY MAINTENA FOR SCHIZOAFFECTIVE DISORDER,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
9211,LIVER FUNCTION TESTS WERE SIGNIFICANTLY ELEVATED,Liver function test increased,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10077692
9219,METHYLPREDNISOLONE FOR THE TREATMENT OF AGVHD,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
9238,SPRUE-LIKE ENTEROPATHY ASSOCIATED TO TAKING OLMESATRAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
9281,WEARING OFF INCREASING,Therapeutic response shortened,WEARING OFF EFFECT,THERAPEUTIC RESPONSE SHORTENED,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063660,10078575,10063660
9348,"SPINE COMPRESSION AT T8,10, 12 AND L5",Spinal flattening,THORACIC SPINE FLATTENING,SPINAL FLATTENING,SPINE AND NECK DEFORMITIES,MUSCULOSKELETAL AND CONNECTIVE TISSUE DEFORMITIES (INCL INTERVERTEBRAL DISC DISORDERS),10028395,10067700,10077756,10067700
9350,ABIRATERONE-INDUCED MINERALOCORTICOID EXCESS SYNDROME,Acquired apparent mineralocorticoid excess,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ADRENAL CORTICAL HYPERFUNCTIONS,ADRENAL GLAND DISORDERS,10014698,10080230,10080230,10080230
9364,THE PATIENT RECEIVED MIDAZOLAM TO PROVIDE ANALGESIA AND REDUCE ANXIETY,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
9478,PYLORIC METAPLASIA,Intestinal metaplasia,INTESTINAL METAPLASIA,INTESTINAL METAPLASIA,GASTROINTESTINAL MUCOSAL DYSTROPHIES AND SECRETION DISORDERS,GASTROINTESTINAL CONDITIONS NEC,10017947,10068411,10068411,10068411
9515,HIV-1 PERSISTENT VIREMIA,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
9523,THERAPY-RESISTANT MULTI-ORGAN FAILURE,Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
9564,"DESPITE FUROSEMIDE AND IRBESARTAN, DYSPNEA AND EDEMA PERSISTED",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
9628,DEPERSONALIZATION,Depersonalisation/derealisation disorder,DEPERSONALIZATION,DEPERSONALISATION/DEREALISATION DISORDER,DISSOCIATIVE STATES,DISSOCIATIVE DISORDERS,10037175,10012357,10077805,10012359
9631,LISINOPRIL FOR MILD MICROALBUMINURIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
9649,MILDLY DECREASED GROWTH VELOCITY FOLLOWING OFF LABEL USE,Growth failure,GROWTH FAILURE,GROWTH FAILURE,MUSCULOSKELETAL AND CONNECTIVE TISSUE CONDITIONS NEC,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS NEC,10028395,10071095,10071095,10071095
9653,FAILED TO RESPOND,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
9695,VENLAFAXINE-INDUCED REM SLEEP BEHAVIORAL DISORDER,Rapid eye movement sleep behaviour disorder,RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER,RAPID EYE MOVEMENT SLEEP BEHAVIOUR DISORDER,PARASOMNIAS,SLEEP DISORDERS AND DISTURBANCES,10037175,10077299,10077299,10077300
9744,FIXED DRUG ERYTHEMA,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
9761,"MMF, CICLOSPORIN, CLOBETASOL AND RITUXIMAB USED FOR SYSTEMIC LUPUS ERYTHEMATOSUS (DRUG USE FOR UNAPPROVED INDICATION) WITH NO ADR",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
9805,GROWTH FAILURE,growth failure,GROWTH FAILURE,GROWTH FAILURE,MUSCULOSKELETAL AND CONNECTIVE TISSUE CONDITIONS NEC,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS NEC,10028395,10071095,10071095,10071095
9837,URINE CONTAINED BILIRUBIN,Bilirubin urine present,BILIRUBIN URINE PRESENT,BILIRUBIN URINE PRESENT,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077356,10077356,10077356
9856,HYPOCHONDRIAC FEARS,Hypochondriasis ,HYPOCHONDRIASIS,ILLNESS ANXIETY DISORDER,SOMATIC SYMPTOM DISORDERS,SOMATIC SYMPTOM AND RELATED DISORDERS,10037175,10020965,10078077,10020965
9891,FRUSTRATION,Frustration tolerance decreased,FRUSTRATION,FRUSTRATION TOLERANCE DECREASED,EMOTIONAL AND MOOD DISTURBANCES NEC,MOOD DISORDERS AND DISTURBANCES NEC,10037175,10064862,10077753,10064862
9941,ARIPIPRAZOLE USED FOR PITT-HOPKINS SYNDROME,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
9995,DENTAL IMPLANT FAILURE,Dental restoration failure,DENTAL IMPLANT FAILED,DENTAL RESTORATION FAILURE,GASTROINTESTINAL AND HEPATOBILIARY PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10012324,10078978,10012324
9997,PRODUCT USE IN UNAPPROVED INDICATION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
9998,NEUROSARCOIDOSIS,Neurosarcoidosis,NEUROSARCOIDOSIS,NEUROSARCOIDOSIS,CENTRAL NERVOUS SYSTEM INFLAMMATORY DISORDERS NEC,CENTRAL NERVOUS SYSTEM INFECTIONS AND INFLAMMATIONS,10029205,10078011,10078011,10078011
10073,HIV-1 PERSISTENT VIREMIA,HIV viraemia,HIV VIRAEMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077716
10106,ADVANCED EMPD THAT WERE SUCCESSFULLY CONTROLLED BY DOCETAXEL WITH CISPLATIN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
10323,METHOTREXATE FOR JUVENILE IDIOPATHIC ARTHRITIS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
10421,FACIAL DROOP WITH FLACCID DYSARTHRIA DUE TO TUBERCULOUS MYOPATHY,facial droop,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016044,10016062,10016044
10449,USING AMOXICILLIN DURING INFECTIOUS MONONUCLEOSIS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
10451,GROWTH FAILURE,Growth failure,GROWTH FAILURE,GROWTH FAILURE,MUSCULOSKELETAL AND CONNECTIVE TISSUE CONDITIONS NEC,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS NEC,10028395,10071095,10071095,10071095
10459,ACUTE TUBULAR INJURY,Renal tubular injury,RENAL TUBULAR INJURY,RENAL TUBULAR INJURY,RENAL VASCULAR AND ISCHAEMIC CONDITIONS,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10078933,10078933,10078933
10505,BACLOFEN USED FOR PAIN OF THE CERVICAL SPINE AND SHOULDERS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
10533,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
10537,CYTOGENETIC RESPONSE LOSS,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
10840,PATIENT WAS UNABLE TO WALK,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
10854,THE PATIENT RAPIDLY DEVELOPED MULTIPLE ORGAN FAILURE FOLLOWING LACTIC ACIDOSIS,Multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
10912,POOR AUTONOMY,Loss of personal independence in daily activities,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10079487,10079487,10079487
10943,ADULT ONSET STILL'S DISEASE WORSENED FOLLOWING PREDNISONE REDUCTION AND AGAIN AGGRAVATION AFTER DOSE INCREMENT DUE TO TREATMENT FAILURE,Still's disease,ADULT ONSET STILL'S DISEASE,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10079456,10042061,10079456
11024,BLOODY VOMIT,Discoloured vomit,DISCOLOURED VOMIT,DISCOLOURED VOMIT,NAUSEA AND VOMITING SYMPTOMS,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10079120,10079120,10079120
11186,SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
11270,MILD NORMOCHROMIC ANEMIA OF 104 G/L DUE TO GASTROINTESTINAL BLEEDING FOLLOWING TREATMENT WITH IBUPROFEN,normochromic anaemia,NORMOCHROMIC ANAEMIA,NORMOCHROMIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029782,10029782,10029782
11273,HYPERLEUKOCYTOSIS,Hyperleukocytosis,HYPERLEUKOCYTOSIS,HYPERLEUKOCYTOSIS,LEUKOCYTOSES NEC,WHITE BLOOD CELL DISORDERS,10005329,10078862,10078862,10078862
11316,OLMESARTAN-INDUCED ENTEROCOLOPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
11331,MULTIORGAN FAILURE DUE TO SHOCK AND CARDIORESPIRATORY ARREST,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
11342,DRUG ADMINISTRATION TO A NURSING WOMAN,Exposure during breast feeding,EXPOSURE DURING BREAST FEEDING,MATERNAL EXPOSURE DURING BREAST FEEDING,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10071402,10080752,10071402
11458,NEONATAL HEPATOTOXICITY,Neonatal toxicity,NEONATAL TOXICITY,NEONATAL TOXICITY,POISONING AND TOXICITY,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10078986,10078986,10078986
11487,REBOUND INFLAMATION IN FORM OF FRESH KPS IN ANTERIOR SEGMENT EXAMINATION,Keratic precipitates,KERATIC PRECIPITATES,KERATIC PRECIPITATES,"CORNEAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION","ANTERIOR EYE STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION",10015919,10053703,10053703,10053703
11561,PRODUCT USE IN UNAPPROVED INDICATION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
11566,FACIAL PARALYSIS,Facial paralysis,FACIAL PARALYSIS,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016062
11613,PARVIMONAS MICRA INFECTION DUE TO WORSENING OF RIGHT EMPYEMA,Parvimonas infection,PARVIMONAS INFECTION,PARVIMONAS INFECTION,BACTERIAL INFECTIONS NEC,BACTERIAL INFECTIOUS DISORDERS,10021881,10078106,10078106,10078106
11670,MULTIPLE ORGAN FAILURE,Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
11673,TAXANE-INDUCED PERIARTICULAR THENAR ERYTHEMA AND ONYCHOLYSIS SYNDROME (GRADE 3),Periarticular thenar erythema with onycholysis,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10078288,10078288,10078288
11746,CONTRAINDICATED DRUG ADMINISTERED,contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
11826,MYCOPHENOLATE MOFETIL USED FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
11840,MULTIPLE ORGAN DYSFUNCTION SYNDROME FOLLOWING SEPTIC SHOCK,Multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
11849,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10078117,10078117,10078117
11895,PATERNAL EXPOSURE BEFORE PREGNANCY,Paternal exposure before pregnancy,PATERNAL EXPOSURE BEFORE PREGNANCY,PATERNAL EXPOSURE BEFORE PREGNANCY,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080093,10080093,10080093
11909,LACK OF COOPERATION,Patient uncooperative,PATIENT UNCOOPERATIVE,PATIENT UNCOOPERATIVE,SOCIAL ISSUES NEC,LIFESTYLE ISSUES,10041244,10077706,10077706,10077706
11970,SMALL AMOUNT OF FREE FUILD IN THE ABDOMINAL CAVITY,Intra-abdominal fluid collection,INTRA-ABDOMINAL FLUID COLLECTION,INTRA-ABDOMINAL FLUID COLLECTION,PERITONEAL AND RETROPERITONEAL DISORDERS,PERITONEAL AND RETROPERITONEAL CONDITIONS,10017947,10078659,10078659,10078659
11972,USE FOR ORAL CARE (PREVENTION OF INFECTION IN INTENSIVE CARE UNIT),Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
12002,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
12165,HER PAIN WAS STILL SEVERE AND UNCONTROLLED,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
12202,FRUSTRATION,Frustration tolerance decreased,FRUSTRATION,FRUSTRATION TOLERANCE DECREASED,EMOTIONAL AND MOOD DISTURBANCES NEC,MOOD DISORDERS AND DISTURBANCES NEC,10037175,10064862,10077753,10064862
12262,LATE HYPOXIC CARDIAC ARREST SECONDARY TO CRITICAL ILLNESS POLYNEUROMYOPATHY DUE TO SELFPOISONING WITH BACLOFEN,Intensive care unit acquired weakness,CRITICAL ILLNESS POLYNEUROMYOPATHY,INTENSIVE CARE UNIT ACQUIRED WEAKNESS,ACUTE POLYNEUROPATHIES,PERIPHERAL NEUROPATHIES,10029205,10078315,10077255,10078315
12321,CEFOTAXIM USED FOR TREATMENT OF ACUTE RESPIRATORY FAILURE AND COPD,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
12346,CODEINE USED FOR MUSCULOSKELETAL PAIN,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
12397,LITHIUM-INDUCED END STAGE RENAL DISEASE,End stage renal disease,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
12453,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
12455,NORMOCHROMIC ANEMIA  (HB-7 G),Normochromic anaemia,NORMOCHROMIC ANEMIA,NORMOCHROMIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029782,10029782,10054484
12537,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
12547,POSITIVE PSYCHOTIC SYMPTOMS FOLLOWING DELIVERY,Psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
12641,MILD TO MODERATE MENTAL RETARDATION FOLLOWING DRUG EXPOSURE IN UTERO,mental retardation,MENTAL RETARDATION,INTELLECTUAL DISABILITY,INTELLECTUAL DISABILITIES,MENTAL IMPAIRMENT DISORDERS,10029205,10027378,10067989,10027378
12669,DRUG EXPOSURE VIA BREAST MILK WITH NO ADR,drug exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
12682,NO CLINICAL AND RADIOLOGICAL RESPONSE WAS SEEN,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
12703,METHOTREXATE USED FOR JUVENILE DERMATOMYOSITIS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
12758,SEVERE MULTI-ORGAN FAILURE DUE TO SEVERE CIRCULATORY SHOCK,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
12829,DID NOT ACHIEVE RESPONSE TO TREATMENT,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
12850,"DRUG INTERACTION BETWEEN ASPIRIN, DIPYRIDAMOL AND CLOPIDOGREL",Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
12866,SEVERAL AREAS OF T2/FLAIR HYPERINTENSITY IN THE SUPRATENTORIAL AND INFRATENTORIAL BRAIN WITHOUT ENHANCEMENT OR DIFFUSION RESTRICTION,several areas of T2/FLAIR hyperintensity in the supratentorial and infratentorial brain without enhancement or diffusion restriction,HYPERINTENSITY IN BRAIN DEEP NUCLEI,HYPERINTENSITY IN BRAIN DEEP NUCLEI,STRUCTURAL BRAIN DISORDERS NEC,STRUCTURAL BRAIN DISORDERS,10029205,10079392,10079392,10079392
12896,MYCOPHENOLATE MOFETIL USED FOR OCULAR CICATRICIAL PEMPHIGOID,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
12995,BULLOUS FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
13093,NON RESPONDENT TO CLOPIDOGREL THERAPY,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
13134,STABLE DISEASE/NO RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
13160,MULTI-ORGAN FAILURE DUE TO HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Multi-organ failure due to haemophagocytic lymphohistiocytosis,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
13239,ATYPICAL HEMOLYTIC UREMIC SYNDROME (SEUA),atypical hemolytic uremic syndrome,ATYPICAL HEMOLYTIC UREMIC SYNDROME,ATYPICAL HAEMOLYTIC URAEMIC SYNDROME,ANAEMIAS HAEMOLYTIC MECHANICAL FACTOR,HAEMOLYSES AND RELATED CONDITIONS,10005329,10079841,10079840,10079841
13255,HARDLY STAND UP AND UNABLE TO WALK,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
13327,INITIATED HER ON COT BY INDEFINITELY EXTENDING HER COURSE OF OXYCODONE AT AN INCREASED DOSE,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
13347,PATIENT FELT LAST FETAL MOVEMENTS WHEN SHE TOOK FINAL DOSES OF ACETAMINOPHEN,Foetal movement disorder,FETAL MOVEMENT DISORDER,FOETAL MOVEMENT DISORDER,DYSKINESIAS AND MOVEMENT DISORDERS NEC,MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10077576,10077576,10077584
13379,LITHIUM-INDUCED END STAGE RENAL DISEASE,end stage renal disease,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
13380,TENOFOVIR DISOPROXIL FUMARATE-ASSOCIATED RENAL TUBULAR DYSFUNCTION,Renal tubular dysfunction,RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10050335,10050335,10050335
13428,"MULTIPLE FIXED DRUG ERUPTION ON ORAL MUCOSA, TRUNK AND EXTREMITIES DUE TO LEVOFLOXACIN",fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
13440,ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS),Atypical haemolytic uraemic syndrome,ATYPICAL HEMOLYTIC UREMIC SYNDROME,ATYPICAL HAEMOLYTIC URAEMIC SYNDROME,ANAEMIAS HAEMOLYTIC MECHANICAL FACTOR,HAEMOLYSES AND RELATED CONDITIONS,10005329,10079840,10079840,10079841
13493,RESPIRATORY DISTRESS DUE TO BILATERAL CHOANAL ATRESIA FOLLOWING DRUG EXPOSURE IN UTERO,respiratory distress due to bilateral choanal atresia following drug exposure in utero,RESPIRATORY DISTRESS NEONATAL,NEONATAL RESPIRATORY DISTRESS,NEONATAL HYPOXIC CONDITIONS,NEONATAL RESPIRATORY DISORDERS,10038738,10038688,10028973,10038688
13694,IMPAIRED ACTIVITIES OF DAILY LIVING,Activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
13712,FATTY LIVER,fatty liver,NON-ALCOHOLIC FATTY LIVER,NON-ALCOHOLIC FATTY LIVER,HEPATOCELLULAR DAMAGE AND HEPATITIS NEC,HEPATIC AND HEPATOBILIARY DISORDERS,10019805,10029530,10029530,10029530
13757,MULTI-ORGAN FAILURE FOLLOWING ACUTE DRUG TOXICITY,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
13791,PATIENT BECOME NON AMBULATORY,Unable to walk,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10049278,10017581,10049278
13876,HYPERLEUCOCYTOSIS,Hyperleukocytosis,HYPERLEUKOCYTOSIS,HYPERLEUKOCYTOSIS,LEUKOCYTOSES NEC,WHITE BLOOD CELL DISORDERS,10005329,10078862,10078862,10078862
14070,DRUG USE FOR UNAPPROVED INDICATION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
14110,CROSS REACTIVITY TO CEFACLOR AND CEFALEXIN,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
14151,RIGHT ATRIUM ENLARGEMENT,atrial enlargement,ATRIAL ENLARGEMENT,ATRIAL ENLARGEMENT,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10079340,10079340,10079340
14280,BILATERAL FACIAL DROOPING,Facial paralysis,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016044
14342,SEVERE ENTEROPATHY WITH VILLOUS ATROPHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
14447,SPRUE-LIKE ENTEROPATHY ASSOCIATED TO TAKING OLMESARTAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
14492,DIFFUSE SYSTEMIC SCLEROSIS AND ITS WORSENING FOLLOWING LACK OF DRUG EFFECT,Systemic scleroderma,DIFFUSE SYSTEMIC SCLEROSIS,SYSTEMIC SCLERODERMA,CONNECTIVE TISSUE DISORDERS NEC,CONNECTIVE TISSUE DISORDERS (EXCL CONGENITAL),10028395,10012977,10078638,10012977
14557,PROXIMAL TUBULAR DYSFUNCTION,proximal renal tubular dysfunction,PROXIMAL RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10037081,10050335,10037081
14588,CISPLATIN-INDUCED ATYPICAL HEMOLYTIC UREMIC SYNDROME,atypical hemolytic uremic syndrome,ATYPICAL HEMOLYTIC UREMIC SYNDROME,ATYPICAL HAEMOLYTIC URAEMIC SYNDROME,ANAEMIAS HAEMOLYTIC MECHANICAL FACTOR,HAEMOLYSES AND RELATED CONDITIONS,10005329,10079841,10079840,10079841
14613,LINEZOLID USED MYCOBACTERIUM CHELONAE INFECTION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
14676,"TOBRAMYCIN, VITAMIN A, DEXAMETHASONE, FLUOROMETHOLONE, METRONIDAZOLE, BETAMETHASONE",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
14769,BLEOMYCIN ADMINISTERED FOR VENOUS MALFORMATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
14852,"CHRONIC RHINOSINUSITIS, NASAL POLYPOSIS",Chronic rhinosinusitis with nasal polyps,CHRONIC RHINOSINUSITIS WITH NASAL POLYPS,CHRONIC RHINOSINUSITIS WITH NASAL POLYPS,PARANASAL SINUS DISORDERS (EXCL INFECTIONS AND NEOPLASMS),UPPER RESPIRATORY TRACT DISORDERS (EXCL INFECTIONS),10038738,10080060,10080060,10080060
14927,INCREASED HYPERAUTOFLUORESCENCE IN LEFT EYE,Fundus autofluorescence,FUNDUS AUTOFLUORESCENCE,FUNDUS AUTOFLUORESCENCE,OPHTHALMIC HISTOPATHOLOGY AND IMAGING PROCEDURES,"NEUROLOGICAL, SPECIAL SENSES AND PSYCHIATRIC INVESTIGATIONS",10022891,10078792,10078792,10078792
14966,REDUCED FACIAL EXPRESSION/HYPOMIMIA,reduced facial expression,REDUCED FACIAL EXPRESSION,REDUCED FACIAL EXPRESSION,PARKINSON'S DISEASE AND PARKINSONISM,MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10078576,10078576,10078576
15058,RECURRENCE OF NEUROMYELITIS OPTICA SPECTRUM DISORDER DUE TO PERSISTENT DENGUE AND NEW CMV INFECTION,Neuromyelitis optica spectrum disorder,NEUROMYELITIS OPTICA SPECTRUM DISORDER,NEUROMYELITIS OPTICA SPECTRUM DISORDER,DEMYELINATING DISORDERS NEC,DEMYELINATING DISORDERS,10029205,10077875,10077875,10077875
15064,ENALAPRIL WAS INITIATED TO TRY TO REDUCE THE PROTEINURIA,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
15137,"RELAPSE OF IGG4 RELATED LUNG DISEASE FOLLOWING SUBTHERAPEUTIC RESPONSE OF IMMUNOSUPPRESSIVE AGENTS, INCLUDING GLUCOCORTICOIDS",immunoglobulin G4 related disease,IMMUNOGLOBULIN G4 RELATED DISEASE,IMMUNOGLOBULIN G4 RELATED DISEASE,CONNECTIVE TISSUE DISORDERS NEC,CONNECTIVE TISSUE DISORDERS (EXCL CONGENITAL),10028395,10077271,10077271,10077271
15145,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
15165,MAXILLARY SINUS PAIN,sinus pain,SINUS PAIN,SINUS PAIN,UPPER RESPIRATORY TRACT SIGNS AND SYMPTOMS,RESPIRATORY TRACT SIGNS AND SYMPTOMS,10038738,10040747,10040747,10040747
15170,MULTIPLE ORGAN FAILURE FOLLOWING OPPORTUNISTIC INFECTIONS FOLLOWING IMMUNOSUPPRESSIVE THERAPIES,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
15212,PERIPHERAL ARTERY OCCLUSIVE DISEASE,Peripheral artery occlusion,PERIPHERAL ARTERY OCCLUSION,PERIPHERAL ARTERY OCCLUSION,"PERIPHERAL VASOCONSTRICTION, NECROSIS AND VASCULAR INSUFFICIENCY","ARTERIOSCLEROSIS, STENOSIS, VASCULAR INSUFFICIENCY AND NECROSIS",10047065,10057525,10057525,10057525
15237,RESPIRATORY PROBLEMS,Neonatal respiratory distress,NEONATAL RESPIRATORY DISTRESS,NEONATAL RESPIRATORY DISTRESS,NEONATAL HYPOXIC CONDITIONS,NEONATAL RESPIRATORY DISORDERS,10038738,10028973,10028973,10028973
15243,ABIRATERONE-INDUCED MINERALOCORTICOID EXCESS SYNDROME,Acquired apparent mineralocorticoid excess,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ADRENAL CORTICAL HYPERFUNCTIONS,ADRENAL GLAND DISORDERS,10014698,10080230,10080230,10080230
15478,MESENTERIC ARTERY ANEURYSM,Mesenteric artery aneurysm,MESENTERIC ARTERY ANEURYSM,MESENTERIC ARTERY ANEURYSM,GASTROINTESTINAL VASCULAR MALFORMATIONS,GASTROINTESTINAL VASCULAR CONDITIONS,10017947,10079556,10079556,10079556
15497,OMEPRAZOLE GIVEN AS A TREATMENT FOR COLD,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
15530,TUMEFACTIVE DEMYELINATING LESIONS IN THE LEFT TEMPORAL LOBE,Tumefactive multiple sclerosis,TUMEFACTIVE MULTIPLE SCLEROSIS,TUMEFACTIVE MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS ACUTE AND PROGRESSIVE,DEMYELINATING DISORDERS,10029205,10078556,10078556,10078556
15546,"HE HAD BEEN PREVIOUSLY (ERRONEOUSLY) DIAGNOSED AS SUFFERING FROM ""SOLAR"" ANGIO-EDEMA AND HAD BEEN TREATED WITH DESLORATADINE",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
15640,PRODUCT USE IN UNAPPROVED INDICATION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
15675,PATIENT TREATED WITH PREDNISONE DURING AN INFECTIOUS STATE FOLLOWING MIS-DIAGNOSIS (MEDICATION ERROR),Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
15701,MULTIPLE ORGAN FAILURE DUE TO DISSEMINATED INTRAVASCULAR COAGULATION AND SEPTIC SHOCK,multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
15813,PARTIAL RESPONSE,partial response,PARTIAL RESPONDER TO THERAPY,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10066429,10078115,10066429
15890,RHINITIS MEDICAMENTOSA,Rebound nasal congestion,RHINITIS MEDICAMENTOSA,REBOUND NASAL CONGESTION,NASAL CONGESTION AND INFLAMMATIONS,UPPER RESPIRATORY TRACT DISORDERS (EXCL INFECTIONS),10038738,10039090,10079593,10039090
15914,CEFTRIAXONE INDUCED PSEUDOLITHIASIS,Pseudocholelithiasis,PSEUDOCHOLELITHIASIS,PSEUDOCHOLELITHIASIS,CHOLECYSTITIS AND CHOLELITHIASIS,GALLBLADDER DISORDERS,10019805,10066884,10066884,10066884
15972,EUGLYCAEMIC DIABETIC KETOACIDOSIS,Euglycaemic diabetic ketoacidosis,EUGLYCAEMIC DIABETIC KETOACIDOSIS,EUGLYCAEMIC DIABETIC KETOACIDOSIS,DIABETIC COMPLICATIONS NEC,DIABETIC COMPLICATIONS,10027433,10080061,10080061,10080061
16006,"DESPITE THESE TREATMENTS, PATIENT EXPERIENCED RELAPSE OF ADULT STILL'S DISEASE",Still's disease,ADULT ONSET STILL'S DISEASE,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10079456,10042061,10079456
16039,"FEMALE PATIENT WHO HAD COTARD'S SYNDROME, AND SHOWN CLINICAL IMPROVEMENT UPON BEING TREATED WITH BOTH DULOXETINE AND AMISULPRIDE.",Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
16095,MASSIVE THROMBOSIS OF THE INTRAVENOUS PORT,Catheter related thrombosis,CATHETER RELATED THROMBOSIS,DEVICE RELATED THROMBOSIS,VASCULAR COMPLICATIONS ASSOCIATED WITH DEVICE,COMPLICATIONS ASSOCIATED WITH DEVICE,10018065,10077456,10077455,10077456
16141,"IN JUL YEAR X, TREATMENT RESPONSE WAS EVALUATED AS PD BECAUSE OF INCREASED PRIMARY AND LUNG METASTATIC LESIONS",Tumour pseudoprogression,TUMOUR PSEUDOPROGRESSION,TUMOUR PSEUDOPROGRESSION,ONCOLOGIC COMPLICATIONS AND EMERGENCIES,NEOPLASM RELATED MORBIDITIES,10029104,10077472,10077472,10077472
16175,SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
16188,RIGHT FACIAL DROOP,Facial paralysis,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016044
16327,"LEFT VENTRICULAR ENLARGEMENT, LEFT ATRIAL ENLARGEMENT",Left ventricular enlargement,LEFT VENTRICULAR ENLARGEMENT,LEFT VENTRICULAR ENLARGEMENT,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10050581,10050581,10050581
16351,LOW SERUM CORTISOL,Serum cortisol decreased,SERUM CORTISOL DECREASED,CORTISOL DECREASED,ADRENAL CORTEX TESTS,ENDOCRINE INVESTIGATIONS (INCL SEX HORMONES),10022891,10040218,10011198,10040218
16370,MULTI-ORGAN FAILURE,Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
16388,ANTICHOLINERGIC POISONING CAUSED BY THE SUBSTITUTION OF HYOSCINE HYDROBROMIDE FOR HYOSCINE BUTYLBROMIDE,Product substitution error,PRODUCT SUBSTITUTION ERROR,PRODUCT SUBSTITUTION ERROR,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10078984,10078984,10078984
16422,TENOFOVIR DISOPROXIL FUMARATE-ASSOCIATED RENAL TUBULAR DYSFUNCTION,Renal tubular dysfunction,RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10050335,10050335,10050335
16439,FAILED TO RESPOND TO MEDICATION,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
16456,DRUG USED FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
16477,IMMUNOSUPPRESSIVE TREATMENT USED IN DEVICâ€™S SYNDROME (NEUROMYELITIS OPTICA),Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
16504,ATEROSCLEROTIC DISORDER OF ARTERIAL SYSTEM OF LOWER EXTREMITIES (OCCLUSION OF PROXIMAL ARTERIA FEMORALIS SUPERFICIALIS),Superficial femoral artery occlusion,SUPERFICIAL FEMORAL ARTERY OCCLUSION,PERIPHERAL ARTERY OCCLUSION,"PERIPHERAL VASOCONSTRICTION, NECROSIS AND VASCULAR INSUFFICIENCY","ARTERIOSCLEROSIS, STENOSIS, VASCULAR INSUFFICIENCY AND NECROSIS",10047065,10076842,10057525,10076842
16530,LACK OF EFFICACY (BLOOD PRESSURE 150/90 MMHG),Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
16623,ALTERED COLOR VISION,Dyschromatopsia,COLOR VISION CHANGE,DYSCHROMATOPSIA,COLOUR BLINDNESS (INCL ACQUIRED),VISION DISORDERS,10015919,10068918,10013892,10068914
16652,NON-COELIAC REFRACTORY SPRUE,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
16780,INABILITY TO EITHER STAND OR WALK,unable to walk,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10049278,10017581,10049278
16789,RELAPSE OF NEUROMYELITIS OPTICA ASSOCIATED SPECTRUM DISORDER FOLLOWING LACK OF DRUG EFFECT,Neuromyelitis optica spectrum disorder,NEUROMYELITIS OPTICA SPECTRUM DISORDER RELAPSE,NEUROMYELITIS OPTICA SPECTRUM DISORDER,DEMYELINATING DISORDERS NEC,DEMYELINATING DISORDERS,10029205,10077879,10077875,10077879
16792,DRUG USE FOR UNAPPROVED INDICATION WITH NO ADR,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
16854,REACTION TO DRUG EXCIPIENT,Reaction to drug excipient,REACTION TO DRUG EXCIPIENT,REACTION TO EXCIPIENT,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10037975,10079925,10037975
16878,TONSILS AND PALATOPHARYNGEAL ARCHES ARE RED,Tonsillar erythema,RED TONSILS,TONSILLAR ERYTHEMA,PHARYNGEAL DISORDERS (EXCL INFECTIONS AND NEOPLASMS),UPPER RESPIRATORY TRACT DISORDERS (EXCL INFECTIONS),10038738,10078259,10078256,10078259
16902,RENAL TUBULAR INJURY,renal tubular injury,RENAL TUBULAR INJURY,RENAL TUBULAR INJURY,RENAL VASCULAR AND ISCHAEMIC CONDITIONS,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10078933,10078933,10078933
16912,GAIT INABILITY/ FUNCTIONAL IMPOTENCE FOLLOWING RUPTURE OF ACHILLES TENDONS,Gait inability,GAIT INABILITY,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10017581
16919,OLMESARTAN INDUCED SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
16946,MULTI ORGAN FAILURE FOLLOWING SEPTIC SHOCK DUE TO LACK OF DRUG EFFECT,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
16962,VIBRIO VULNIFICUS INFECTION,Vibrio vulniï¬cus infection,VIBRIO VULNIFICUS INFECTION,VIBRIO VULNIFICUS INFECTION,VIBRIO INFECTIONS,BACTERIAL INFECTIOUS DISORDERS,10021881,10080490,10080490,10080490
16966,MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS),Multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
16998,MANIC EPISODE WITH PSYCHOTIC SYMPTOMS,Psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
17124,TREATED WITH ASPIRIN FOR ESSENTIAL THROMBOCYTEMIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
17190,PROXIMAL TUBULE MITOCHONDRIAL TOXICITY,Renal tubular dysfunction,PROXIMAL RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10037081,10050335,10037081
17219,PROGRESSION OF IMMUNE-RELATED HEPATITIS DUE TO FAILURE OF LIVER PROTECTION THERAPY AND PREDNISONE THERAPY TO REVERSE THE LIVER INJURY (LACK OF DRUG EFFECT),Immune-mediated hepatitis,IMMUNE-MEDIATED HEPATITIS,IMMUNE-MEDIATED HEPATITIS,HEPATOCELLULAR DAMAGE AND HEPATITIS NEC,HEPATIC AND HEPATOBILIARY DISORDERS,10019805,10078962,10078962,10078962
17238,9 WITNESSED COMPLEX PARTIAL SEIZURES/ SEIZURE INDUCED BY A THERAPEUTIC DOSE OF VENLAFAXINE ER/ VENLAFAXINE-,Focal dyscognitive seizures,COMPLEX PARTIAL SEIZURES,FOCAL DYSCOGNITIVE SEIZURES,PARTIAL COMPLEX SEIZURES,SEIZURES (INCL SUBTYPES),10029205,10010145,10079424,10010145
17334,ACETYLSALICYLIC ACID USED FOR PREVENTION OF PREECLAMPSIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
17373,PROGRESSION (MULTIORGAN FAILURE),Multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
17500,HAD TRIED POLYETHYLENE GLYCOL APPROXIMATELY A YEAR AGO BUT DISCONTINUED IT AFTER A FEW DAYS SECONDARY TO FECAL INCONTINENCE.,Anal incontinence,FECAL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10016092,10077605,10016296
17584,PATERNAL EXPOSURE BEFORE PREGNANCY,Paternal exposure before pregnancy,PATERNAL EXPOSURE BEFORE PREGNANCY,PATERNAL EXPOSURE BEFORE PREGNANCY,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080093,10080093,10080093
17599,MYCOPHENOLATE MOFETIL USED FOR MULTIPHASIC DISSEMINATED ENCEPHALOMYELITIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
17728,HEPATITIS B REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
17830,"RAMIPRIL, DILTIAZEM, CANDESARTAN, SILDENAFIL, BOSENTAN AND MINOCYCLINE HYDROCHLORIDE USED TO TREAT DIGITAL ULCERATION IN SYSTEMIC SCLEROSIS LEADING TO MINOCYCLINE INDUCED HYPERPIGMENTATION",Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
17832,NEUROMYELITIS OPTICA SPECTRUM DISORDER RELAPSE,Neuromyelitis optica spectrum disorder,NEUROMYELITIS OPTICA SPECTRUM DISORDER RELAPSE,NEUROMYELITIS OPTICA SPECTRUM DISORDER,DEMYELINATING DISORDERS NEC,DEMYELINATING DISORDERS,10029205,10077879,10077875,10077879
17947,MULTIFOCAL FIXED DRUG ERUPTION,fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
17969,MITOMYCIN C USED FOR ADVANCED UNCONTROLLED PRIMARY OPEN-ANGLE GLAUCOMA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
18009,HEPATITIS B VIRUS REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
18116,SYSTEMIC SCLEROSIS PROGRESSION FOLLOWING DRUG EXPOSURE DURING PREGNANCY,Systemic sclerosis,SYSTEMIC SCLEROSIS,SYSTEMIC SCLERODERMA,CONNECTIVE TISSUE DISORDERS NEC,CONNECTIVE TISSUE DISORDERS (EXCL CONGENITAL),10028395,10042953,10078638,10042953
18173,ATEROSCLEROTIC DISORDER OF ARTERIAL SYSTEM OF LOWER EXTREMITIES (OCCLUSION OF PROXIMAL ARTERIA FEMORALIS SUPERFICIALIS),Peripheral artery occlusion,PERIPHERAL ARTERY OCCLUSION,PERIPHERAL ARTERY OCCLUSION,"PERIPHERAL VASOCONSTRICTION, NECROSIS AND VASCULAR INSUFFICIENCY","ARTERIOSCLEROSIS, STENOSIS, VASCULAR INSUFFICIENCY AND NECROSIS",10047065,10057525,10057525,10057525
18209,PATIENT DIAGNOSED WITH DIAGNOSIS OF SATOYOSHI SYNDROME/GIVEN ORAL PREDNISOLONE/RESOLUTION OF HER SYMTOMS,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
18229,REFRACTORY GRAFT-VERSUS-HOST DISEASE,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
18269,MULTIPLE ORGAN DYSFUNCTION SYNDROME,Multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
18483,MULTI ORGAN FAILURE FOLLOWING CARDIOGENIC SHOCK,multi organ failure,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028151,10077361,10028151
18526,BLOOD CORTISOL LEVEL DECREASED (1 MICROGRAM/DL),Blood cortisol decreased ,BLOOD CORTISOL DECREASED,CORTISOL DECREASED,ADRENAL CORTEX TESTS,ENDOCRINE INVESTIGATIONS (INCL SEX HORMONES),10022891,10005457,10011198,10005457
18539,MAJOR MOLECULAR RESPONSE (MMR) LOSS,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
18563,FLARE-UP OF ADULT STILL'S DISEASE/ RELAPSED ADULT STILL'S DISEASE,Still's disease,ADULT ONSET STILL'S DISEASE,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10079456,10042061,10079456
18589,HIV-1 VIREMIA FOLLOWING LACK OF DRUG EFFECT,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
18745,NO RESPONSE,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
18752,"PSYCHOTIC SYMPTOMS GOT PARTIAL REMISSION/ POOR RESPONSE TO HIGH DOSAGES OF RISPERIDONE, ZOTEPINE, QUETIAPINE, OLANZAPINE, PALIPERIDONE, HALOPERIDOL,",Therapy partial responder,PARTIAL RESPONDER TO THERAPY,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10066429
18811,SLEEP DISRUPTION,Non-24-hour sleep-wake disorder,DISRUPTIONS OF 24 HOUR SLEEP-WAKE CYCLE,NON-24-HOUR SLEEP-WAKE DISORDER,DISTURBANCES IN SLEEP PHASE RHYTHM,SLEEP DISTURBANCES (INCL SUBTYPES),10029205,10013419,10078086,10013419
18830,WORSENING OF FACIAL PARALYSIS (HOUSE BRACKMANN GRADE IV),Facial paralysis,FACIAL PARALYSIS,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016062
18887,BOWEL INCONTINENCE,Bowel incontinence,BOWEL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10050492,10077605,10050492
18902,MULTIPLE ORGAN FAILURE FOLLOWING SEPTIC SHOCK,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
19004,FIXED DRUG ERUPTION TO PIROXICAM,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
19028,PATIENT HAD SUBGLOTTIC HAEMANGIOMA WITH 70 PERCENT OBSTRUCTION OF THE AIRWAY AND WAS COMMENCED ON PROPRANOLOL,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
19076,LACTATION EXPOSURE,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
19091,CASE OF RHEUMATOID/SHE RECEIVED ASA 80 MG PO QD AND ATORVASTATIN 40 MG/THIS CASE SHOWED AN OVERALL POOR PERFORMANCE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
19152,DRUG CROSS-REACTIVITY,Therapeutic product cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
19205,WE TAPERED TACROLIMUS AND STARTED MIRTAZAPINE AND CIDOFOVIR,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
19280,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
19440,VINORELBINE USED FOR AGGRESSIVE LYMPHOMAS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
19576,ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODIES POSITIVE,Anti-myelin-associated glycoprotein antibodies positive,ANTI-MYELIN-ASSOCIATED GLYCOPROTEIN ANTIBODIES POSITIVE,ANTI-MYELIN-ASSOCIATED GLYCOPROTEIN ANTIBODIES POSITIVE,AUTOIMMUNITY ANALYSES,IMMUNOLOGY AND ALLERGY INVESTIGATIONS,10022891,10078318,10078318,10078318
19587,PREDNISONE USED IN KIDNEY TRANSPLANTATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
19601,MYCOPHENOLATE MOFETIL USED IN ULCERATIVE COLITIS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
19710,NO CLINICAL RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
19765,JET WAS REFRACTORY TO AMIODARONE IN A 2-MONTH OLD PATIENT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
19771,PATIENT UNDER TREATMENT WITH ASPIRIN RECEIVED ALTEPLASE,contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
19775,DORZOLAMIDE INDUCED NORMOCYTIC ANEMIA (82 G/L),Normocytic anaemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029785
19844,EXCESSIVE UTERINE SYSTOLIC FUNCTION,Uterine tachysystole,UTERINE TACHYSYSTOLE,UTERINE TACHYSYSTOLE,MATERNAL COMPLICATIONS OF LABOUR NEC,MATERNAL COMPLICATIONS OF LABOUR AND DELIVERY,10036585,10080022,10080022,10080022
19882,NORMOCYTIC ANEMIA,normocytic anemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029785,10029784,10029785
19951,SEVERE COGNITIVE AND BEHAVIORAL DETERIORATION,Neuropsychiatric symptoms,BEHAVIORAL AND PSYCHIATRIC SYMPTOMS OF DEMENTIA,NEUROPSYCHIATRIC SYMPTOMS,MENTAL DISORDERS DUE TO A GENERAL MEDICAL CONDITION NEC,PSYCHIATRIC DISORDERS NEC,10037175,10066842,10078497,10066844
20026,PATIENT RECEIVED MOXIFLOXACIN MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
20161,HIV-1 PERSISTENT VIREMIA FOLLOWING EMTRICITABINE RESISTANCE,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
20223,SEVERE RESPIRATORY DISTRESS,Respiratory distress neonatal,RESPIRATORY DISTRESS NEONATAL,NEONATAL RESPIRATORY DISTRESS,NEONATAL HYPOXIC CONDITIONS,NEONATAL RESPIRATORY DISORDERS,10038738,10038688,10028973,10038688
20230,HOME MEDICATIONS INCLUDED SODIUM DOCUSATE AND SUCRALAFATE,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
20252,DRUG USE FOR UNAPPROVED INDICATION (BENDAMUSTINE FOR BONE MARROW CONDITIONING REGIMEN),Drug use for unapproved indication (Bendamustine for Bone marrow conditioning regimen),DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
20256,"PERCEPTUAL ABNORMALITIES-NAMELY, VISUAL, AUDITORY",auditory disorder,AUDITORY DISORDER,AUDITORY DISORDER,HEARING DISORDERS NEC,HEARING DISORDERS,10013993,10003778,10003778,10003778
20361,INTERMITTENT ELEVATION OF LIVER FUNCTION TESTS,liver function test increased,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10077692
20380,CROSS REACTIVITY TO CEFACLOR AND CEFALEXIN,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
20410,LITHIUM-INDUCED END STAGE RENAL DISEASE,end stage renal disease,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
20434,ISOSORBIDE DINITRATE THERAPY LED TO A DRAMATIC IMPROVEMENT IN BLOOD PRESSURE,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
20481,RITUXIMAB AND MYCOPHENOLATE MOFETIL USED FOR FOCAL SEGMENTAL GLOMERULAR SCLEROSIS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
20548,"INAPPROPRIATE AND UNNECESSARY USE OF MEDICATIONS/ALL USED TO INDUCE AND MAINTAIN SLEEP: RAMELTEON, TEMAZEPAM, AMITRIPTYLINE, QUETIAPINE, HYDROCORTISONE, ANASTROZOLE, PROGESTERONE, TRYPTOPHAN, MELATONIN (30MG), AND DHEA",Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
20551,ADVANCED EMPD THAT WERE SUCCESSFULLY CONTROLLED BY DOCETAXEL WITH CISPLATIN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
20569,VOCAL TREMOR,laryngeal tremor,LARYNGEAL TREMOR,LARYNGEAL TREMOR,TREMOR (EXCL CONGENITAL),MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10078751,10078751,10078751
20579,MYCOPHENALATE MOFETIL USED FOR OCULAR MUCOUS MEMBRANE PEMPHIGOID,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
20624,PULMONARY NOCARDIOSIS,pulmonary nocardiosis,PULMONARY NOCARDIOSIS,PULMONARY NOCARDIOSIS,NOCARDIA INFECTIONS,BACTERIAL INFECTIOUS DISORDERS,10021881,10080435,10080435,10080435
20698,NO POST-VACCINATION RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
20761,BETAMETHASONE USED FOR TREATMENT OF RIGHT ATRIAL ANGIOSARCOMA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
20812,ACUTE TUBULAR INJURY FOLLOWING OXALATE NEPHROPATHY,Renal tubular injury,RENAL TUBULAR INJURY,RENAL TUBULAR INJURY,RENAL VASCULAR AND ISCHAEMIC CONDITIONS,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10078933,10078933,10078933
20886,PSEUDOTUMOUR CEREBRI SYNDROME,Idiopathic intracranial hypertension,PSEUDOTUMOUR CEREBRI,IDIOPATHIC INTRACRANIAL HYPERTENSION,INCREASED INTRACRANIAL PRESSURE DISORDERS,INCREASED INTRACRANIAL PRESSURE AND HYDROCEPHALUS,10029205,10073807,10078904,10073807
20900,DEVELOPED BRADYCARDIA AND THERE WAS NO RESPONSE TO ATROPINE/ADMINISTRATION OF ATROPINE IN OUR PATIENT DID NOT IMPROVE HIS CLINICAL CONDITION,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
20949,OLANZAPINE USED FOR DEPRESSIVE SYMPTOMS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
21019,CYCLOPHOSPHAMIDE USED FOR TREATMENT OF SARCOIDOSIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
21076,CONTINUING PSYCHOTIC SYMPTOMS,Psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
21134,DRUG USE FOR AN UNAPPROVED INDICATION WITH NO ADVERSE DRUG REACTION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
21155,REVERSIBLE CEFTRIAXONE INDUCED PSEUDOLITHIASIS,Pseudocholelithiasis,PSEUDOCHOLELITHIASIS,PSEUDOCHOLELITHIASIS,CHOLECYSTITIS AND CHOLELITHIASIS,GALLBLADDER DISORDERS,10019805,10066884,10066884,10066884
21159,LOSS OF MOLECULAR RESPONSE,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
21174,CROSS REACTIVITY TO CEFACLOR AND CEFALEXIN,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
21181,HIS LONG TERM MEDICATION CONSISTED OF IBUPROFEN 3 Ã— 800 MG PER DAY FOR CHRONIC PAIN,Product prescribing issue,INAPPROPRIATE PRESCRIBING,PRODUCT PRESCRIBING ISSUE,PRODUCT PRESCRIBING ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10079271,10080459,10079271
21226,ENTERIC PLEXUS NEUROPATHY,Enteric neuropathy,ENTERIC NEUROPATHY,ENTERIC NEUROPATHY,GASTROINTESTINAL ATONIC AND HYPOMOTILITY DISORDERS NEC,GASTROINTESTINAL MOTILITY AND DEFAECATION CONDITIONS,10017947,10080846,10080846,10080846
21261,TENDER JOINTS,Tender joint count,TENDER JOINT COUNT,TENDER JOINT COUNT,MUSCULOSKELETAL AND SOFT TISSUE TESTS NEC,MUSCULOSKELETAL AND SOFT TISSUE INVESTIGATIONS (EXCL ENZYME TESTS),10022891,10078913,10078913,10078913
21502,DRUG PRESCRIBED FOR UNAPPROVED INDICATION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
21600,METHYLPREDNISOLONE PULSES FOR GRANULOMATOSIS WITH POLYANGIITIS AND NEUROLOGICAL IMPAIRMENT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
21627,TENOFOVIR DISOPROXIL FUMARATE- ASSOCIATED RENAL TUBULAR DYSFUNCTION,Renal tubular dysfunction,RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10050335,10050335,10050335
21681,LITTLE PLEURAL THICKENING/PLEURAL REACTION WAS REPORTED IN DEPENDENT PARTS OF THE LEFT LOWER LOBE,pleural thickening,PLEURAL THICKENING,PLEURAL THICKENING,PLEURAL CONDITIONS NEC,PLEURAL DISORDERS,10038738,10035616,10035616,10035616
21694,END-STAGE CHRONIC KIDNEY DISEASE,End stage renal disease,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
21709,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
21716,MULTIORGAN DYSFUNCTION DUE TO SEPTIC SHOCK,Multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
21762,MANUFACTURING FAULT IN SLOW RELEASE PATCH,Manufacturing production issue,MANUFACTURING PRODUCTION ISSUE,MANUFACTURING PRODUCTION ISSUE,MANUFACTURING PRODUCTION ISSUES,"PRODUCT QUALITY, SUPPLY, DISTRIBUTION, MANUFACTURING AND QUALITY SYSTEM ISSUES",10077536,10077799,10077799,10077799
21840,NIFEDIPINE ADMINISTERED TO TREAT PRE-ECLAMPSIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
21858,ABASIA,Abasia,ABASIA,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10049460,10017581,10049460
21885,CIPROFLOXACIN-INDUCED GENERALISED NON-BULLOUS FIXED DRUG ERUPTION,generalised non-bullous fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
21920,24 YRS OLD FEMALE RECEIVED ASPIRIN FOR ANTITHROMBIN DEFICIENCYAND CONCEIVED SHORTLY AFTER,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
21926,ADULT STILL'S DISEASE RELAPSE DESPITE TREATMENT,Still's disease,ADULT ONSET STILL'S DISEASE,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10079456,10042061,10079456
21938,MULTIPLE SYSTEM ORGAN FAILURE,Multi organ failure,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028151,10077361,10028151
21952,ELEVATION OF THE LIVER TESTS,Liver function test increased,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10077692
22005,MULTIPLE ORGAN DYSFUNCTION DUE TO WORSENING OF VIBRIO VULNIFICUS SEPTICEMIA FOLLOWING LACK OF DRUG EFFECT OF ANTIBIOTICS TREATMENT,multiple organ dysfunction due to worsening of Vibrio vulnificus septicemia following lack of drug effect of antibiotics treatment,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
22098,PARVIMONAS MICRA INFECTION,Parvimonas micra infection,PARVIMONAS MICRA INFECTION,PARVIMONAS MICRA INFECTION,BACTERIAL INFECTIONS NEC,BACTERIAL INFECTIOUS DISORDERS,10021881,10078596,10078596,10078596
22159,UNABLE TO WALK,Unable to walk,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10049278,10017581,10049278
22230,NORMOCYTIC AND NORMOCHROMIC ANEMIA,Normochromic anaemia,NORMOCHROMIC ANEMIA,NORMOCHROMIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029782,10029782,10054484
22261,PREDNISOLONE 20 MG PER DAY AND DICLOFENAC HAD NO EFFECT ON JOINT PAIN,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
22311,GENERALIZED FIXED DRUG ERUPTION,Fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
22328,ELEVATED LIVER FUNCTION TESTS,Liver function test increased,LIVER FUNCTION TESTS RAISED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10048556
22376,WORSENING OF HYPEROSMOLAR HYPERGLYCEMIA DUE TO TREATMENT NON-COMPLIANCE WITH INSULIN REGIMENS,Hyperglycaemic hyperosmolar nonketotic syndrome,HYPEROSMOLAR HYPERGLYCAEMIC STATE,HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME,DIABETIC COMPLICATIONS NEUROLOGICAL,DIABETIC COMPLICATIONS,10027433,10076413,10063554,10076413
22534,DOXAZOSIN WAS STARTED FOR REFRACTORY AD,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
22569,OLMESARTAN INDUCED SPRUE-LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
22598,MULTISYSTEM ORGAN FAILURE DUE TO SHOCK,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
22623,GAMBLING/PATHOLOGICAL GAMBLING,Gambling disorder,PATHOLOGICAL GAMBLING,GAMBLING DISORDER,SUBSTANCE RELATED AND ADDICTIVE DISORDERS,PSYCHIATRIC DISORDERS NEC,10037175,10034158,10078070,10034158
22705,ADMINISTRATION OF DRUG CONTRAINDICATED DURING PREGNANCY,contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
22739,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
22791,PATIENT RECEIVED ASPIRIN FOR SYSTEMIC LUPUS ERYTHEMATOSUS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
22875,"LEFT VENTRICULAR ENLARGEMENT, LEFT ATRIAL ENLARGEMENT",Left atrial enlargement,LEFT ATRIAL ENLARGEMENT,LEFT ATRIAL ENLARGEMENT,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10051860,10051860,10051860
22880,NORMOCYTIC ANEMIA (HEMOGLOBIN 9.3 G/DL),Normocytic anaemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029785
22907,DECLINE IN ACTIVITIES OF DAILY LIVING AND INDEPENDENT ACTIVITIES OF DAILY LIVING,Loss of personal independence in daily activities,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
22954,MOXIFLOXACIN USED IN TREATMENT OF MULTIDRUG-RESISTANT TB,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
23047,EUGLYCEMIC DIABETIC KETOACIDOSIS,Euglycemic diabetic ketoacidosis,EUGLYCEMIC DIABETIC KETOACIDOSIS,EUGLYCAEMIC DIABETIC KETOACIDOSIS,DIABETIC COMPLICATIONS NEC,DIABETIC COMPLICATIONS,10027433,10080062,10080061,10080062
23169,WORSENING OF CHIN EDEMA AND LOWER LIP WITH AN AREA OF NECROSIS MEASURING 1CM2/ LOWER LIP NECROSIS DUE TO AGGRAVATION OF LOWER LIP AND CHIN CELLULITIS,Necrotising soft tissue infection,NECROTISING SOFT TISSUE INFECTION,NECROTISING SOFT TISSUE INFECTION,MUSCLE AND SOFT TISSUE INFECTIONS,INFECTIONS - PATHOGEN UNSPECIFIED,10021881,10076637,10076637,10076637
23298,2 DOSES OF ADENOSINE (6 AND 12 MG) WERE ADMINISTERED WITHOUT A THERAPEUTIC EFFECT,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
23308,RBD WITH DREAM-ENACTMENT BEHAVIORS DURING REM SLEEP AND RSWA,Rapid eye movement sleep behaviour disorder,RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER,RAPID EYE MOVEMENT SLEEP BEHAVIOUR DISORDER,PARASOMNIAS,SLEEP DISORDERS AND DISTURBANCES,10037175,10077299,10077299,10077300
23313,DYSCHROMATOPSIA,Dyschromatopsia,DYSCHROMATOPSIA,DYSCHROMATOPSIA,COLOUR BLINDNESS (INCL ACQUIRED),VISION DISORDERS,10015919,10013892,10013892,10013892
23332,"YELLOWISH, ABUNDANT EXUDATE OF UNCHARACTERISTIC ODOR AND OTHER LESIONS",Genital odor,GENITAL ODOR,GENITAL ODOUR,REPRODUCTIVE TRACT SIGNS AND SYMPTOMS NEC,REPRODUCTIVE TRACT DISORDERS NEC,10038604,10080417,10080408,10080417
23345,ABNORMAL BASAL CORTISOL SERUM LEVELS,Cortisol abnormal,SERUM CORTISOL ABNORMAL,CORTISOL ABNORMAL,ADRENAL CORTEX TESTS,ENDOCRINE INVESTIGATIONS (INCL SEX HORMONES),10022891,10040217,10011196,10040217
23432,LARGE AMOUNT OF BLOODY RESIDUE IN THE STOMACH,Gastric residual increased,GASTRIC RESIDUAL INCREASED,GASTRIC RESIDUAL INCREASED,GASTROINTESTINAL FUNCTION DIAGNOSTIC PROCEDURES,GASTROINTESTINAL INVESTIGATIONS,10022891,10079783,10079783,10079783
23460,WORSENING OF CHARCOT MARIE TOOTH SYNDROME,Hereditary motor and sensory neuropathy,CHARCOT-MARIE-TOOTH DISEASE,HEREDITARY MOTOR AND SENSORY NEUROPATHY,PERIPHERAL NERVOUS SYSTEM DISORDERS CONGENITAL NEC,NEUROLOGICAL DISORDERS CONGENITAL,10010331,10008414,10077306,10008414
23497,MULTI ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
23526,HAMPERING SLEEP PATTERNS AND DAILY ACTIVITIES,Loss of personal independence in daily activities,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
23538,DRUG EXPOSURE VIA BREAST MILK WITH NO ADR,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
23565,HERPES SIMPLEX VIRUS PCR REACTION,Herpes simplex virus test positive,HERPES SIMPLEX VIRUS TEST POSITIVE,HERPES SIMPLEX TEST POSITIVE,VIRUS IDENTIFICATION AND SEROLOGY,MICROBIOLOGY AND SEROLOGY INVESTIGATIONS,10022891,10070233,10077969,10070233
23593,SLATE-GRAY/PURPLISH DISCOLORATED LESION ON HARD PALATE,Oral pigmentation,PALATAL PIGMENTATION,ORAL PIGMENTATION,ORAL SOFT TISSUE SIGNS AND SYMPTOMS,ORAL SOFT TISSUE CONDITIONS,10017947,10077553,10077552,10077553
23602,AHUS REACCURENCE,Atypical haemolytic uraemic syndrome,ATYPICAL HEMOLYTIC UREMIC SYNDROME,ATYPICAL HAEMOLYTIC URAEMIC SYNDROME,ANAEMIAS HAEMOLYTIC MECHANICAL FACTOR,HAEMOLYSES AND RELATED CONDITIONS,10005329,10079840,10079840,10079841
23610,NON-PIGMENTING FIXED DRUG ERUPTION (NPFDE),Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
23611,EXCESSIVE SEDATION,Sedation complication,SEDATION EXCESSIVE,SEDATION COMPLICATION,ANAESTHETIC AND ALLIED PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10056213,10079741,10039898
23635,WHITE MATTER CHANGES SUGGESTING HIV ENCEPHALOPATHY.,HIV encephalopathy,HIV ENCEPHALOPATHY,HIV-ASSOCIATED NEUROCOGNITIVE DISORDER,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10073054,10078164,10073054
23653,FOR INCESSANT FETAL JET,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
23736,VACCINE CONTRAINDICATED FOR USE IN SCID PATIENTS,Contraindicated drug prescribed,CONTRAINDICATED DRUG PRESCRIBED,CONTRAINDICATED DRUG PRESCRIBED,PRODUCT PRESCRIBING ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10078779,10078779,10078779
23766,TEMOZOLOMIDE FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
23829,FECAL INCONTINENCE,fecal incontinence,FECAL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10016296,10077605,10016296
23831,RELAPSE OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS ASSOCIATED PSEUDOTUMOUR FOLLOWING REBOUND EFFECT,eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10078117,10078117,10078117
23875,ONE MALE PATIENT WAS ADMITTED TO INTENSIVE CARE UNIT BECAUSE OF MULTI ORGAN FAILURE DUE TO PARACETAMOL ANAPHYLAXIS (CLAVIEN IV - LIFE THREATENING),Multi organ failure,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028151,10077361,10028151
23891,MULTIPLE ORGAN DYSFUNCTION SYNDROME,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
23908,ORGANIC BRAIN SYNDROME FOLLOWING ACUTE TOXIC PSYCHOSIS,Organic brain syndrome,ORGANIC BRAIN SYNDROME,ORGANIC BRAIN SYNDROME,MENTAL DISORDERS DUE TO A GENERAL MEDICAL CONDITION NEC,PSYCHIATRIC DISORDERS NEC,10037175,10031077,10031077,10031077
23919,"TREATED WITH BOTH ASPIRIN AND CLOPIDOGREL FOR THE INTERMITTENT GAIT INSTABILITIES,",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
23952,PHAEOHYPHOMYCOTIC BRAIN ABSCESS FOLLOWING ADMINISTRATION OF PREDNISONE AND LEFLUNOMIDE,Phaeohyphomycotic brain abscess,PHAEOHYPHOMYCOTIC BRAIN ABSCESS,PHAEOHYPHOMYCOTIC BRAIN ABSCESS,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10080816,10080816,10080816
23987,RESPIRATORY DISTRESS DUE TO BILATERAL CHOANAL ATRESIA FOLLOWING DRUG EXPOSURE IN UTERO,Respiratory distress neonatal,RESPIRATORY DISTRESS NEONATAL,NEONATAL RESPIRATORY DISTRESS,NEONATAL HYPOXIC CONDITIONS,NEONATAL RESPIRATORY DISORDERS,10038738,10038688,10028973,10038688
24000,RUXOLITINIB FOR CORTICOSTEROID REFRACTORY GRAFT VERSUS HOST DISEASE AND PREDNISONE FOR,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24087,ASPIRIN USED AS ANTIPLATELET AGENT AS PROPHYLAXIS FOR CORONARY ARTERY,product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
24122,CEFTRIAXONE-INDUCED PROGRESSIVE PSEUDOLITHIASIS,Pseudocholelithiasis,PSEUDOCHOLELITHIASIS,PSEUDOCHOLELITHIASIS,CHOLECYSTITIS AND CHOLELITHIASIS,GALLBLADDER DISORDERS,10019805,10066884,10066884,10066884
24242,LEFT ATRIAL ENLARGEMENT,Left atrial enlargement,LEFT ATRIAL ENLARGEMENT,LEFT ATRIAL ENLARGEMENT,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10051860,10051860,10051860
24266,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
24341,NO RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
24351,MULTI-SYSTEM ORGAN FAILURE DUE TO RECURRENT MULTI-DRUG RESISTANT K.PNEUMONIAE BACTEREMIA,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
24391,CARDIAC DYSFUNCTION,Cardiac dysfunction,CARDIAC DYSFUNCTION,CARDIAC DYSFUNCTION,CARDIAC DISORDERS NEC,CARDIAC DISORDER SIGNS AND SYMPTOMS,10007541,10079751,10079751,10079751
24395,RECURRENT MULTIFOCAL FIXED DRUG ERUPTION TO CEFTAZIDIME,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
24409,PATHOLOGICAL CHANGES IN THE HEART - INTERSTITIAL ADIPOSE TISSUE HYPERPLASIA,Fatty infiltration of heart,FATTY INFILTRATION OF HEART,CARDIAC STEATOSIS,CARDIOMYOPATHIES,MYOCARDIAL DISORDERS,10007541,10077908,10077905,10077908
24419,SEVERE RENAL OSTEODYSTROPHY,renal osteodystrophy,RENAL OSTEODYSTROPHY,CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER,METABOLIC BONE DISORDERS,BONE DISORDERS (EXCL CONGENITAL AND FRACTURES),10028395,10038489,10078095,10038489
24426,DRUG USE FOR UNAPPROVED INDICATION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24433,MULTI-ORGAN FAILURE,multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
24438,FIXED DRUG ERUPTION,fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
24461,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
24484,MOF,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
24543,ZOLEDRONATE USED FOR CHONDROBLASTOMA,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24577,CLONAZEPAM USED FOR TREATMENT OF SPASTICITY IN CHRONIC SPINAL CORD INJURY,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24580,"USED FOR COUGH,WITH SUBJECTIVE IMPROVEMENT ALMOST IMMEDIATELY AND ABILITY TO SLEEP FOR HOURS UNINTERRUPTED",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24586,MULTI ORGAN FAILURE FOLLOWING GASTOINTESTINAL SYMPTOMS,Multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
24656,NECROTIZING SOFT TISSUE INFECTION,Necrotising soft tissue infection,NECROTIZING SOFT TISSUE INFECTION,NECROTISING SOFT TISSUE INFECTION,MUSCLE AND SOFT TISSUE INFECTIONS,INFECTIONS - PATHOGEN UNSPECIFIED,10021881,10076637,10076637,10076638
24699,MULTIORGAN FAILURE FOLLOWING SEVERE SEPTIC SHOCK,Multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
24739,DRUG USE FOR UNAPPROVED INDICATION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24861,ADVANCED EMPD THAT WERE SUCCESSFULLY CONTROLLED BY DOCETAXEL WITH CISPLATIN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
24900,VACCINE CONTRAINDICATED FOR USE IN SCID PATIENTS,Contraindicated drug prescribed,CONTRAINDICATED DRUG PRESCRIBED,CONTRAINDICATED DRUG PRESCRIBED,PRODUCT PRESCRIBING ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10078779,10078779,10078779
24918,PREDNISONE USED FOR THE TREATMENT OF JUVENILE XANTHOGRANULOMA,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
24931,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
25005,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
25117,"SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROME (SIBO), (OF KLEBSIELLA)",Gastrointestinal bacterial overgrowth,SMALL INTESTINAL BACTERIAL OVERGROWTH,GASTROINTESTINAL BACTERIAL OVERGROWTH,BACTERIAL INFECTIONS NEC,BACTERIAL INFECTIOUS DISORDERS,10021881,10071061,10078158,10071061
25124,BLEOMYCIN USED FOR SERTOLI-LEYDIG OVARIAN TUMOR,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
25134,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
25137,BULLOUS FIXED DRUG ERUPTION FOLLOWING IBUPROFEN INGESTION/ ANAL MUCOSAL LESION AND SIMILAR PENILE INVOLVEMENT,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
25175,INABILITY TO WALK,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
25209,DRUG EXPOSURE VIA BREAST MILK WITH NO ADR,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
25223,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
25326,MILD TO MODERATE MENTAL RETARDATION FOLLOWING DRUG EXPOSURE IN UTERO,mental retardation,MENTAL RETARDATION,INTELLECTUAL DISABILITY,INTELLECTUAL DISABILITIES,MENTAL IMPAIRMENT DISORDERS,10029205,10027378,10067989,10027378
25446,LOMUSTINE USED FOR ACUTE MYELOID LEUKEAMIA,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
25468,CHRONIC FECAL SECRETION OF VACCINE-DERIVED POLIOVIRUS,Fecal incontinence,FECAL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10016296,10077605,10016296
25478,FIXED DRUG ERUPTION FOLLOWING OFF LABEL USE OF AMOXICILLIN AND METAMIZOLE,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
25479,TENOFOVIR DISOPROXIL FUMARATE-ASSOCIATED RENAL TUBULAR DYSFUNCTION,Renal tubular dysfunction,RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10050335,10050335,10050335
25498,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
25519,NEONATAL HYPOCALCEMIA,NEONATAL HYPOCALCEMIA,NEONATAL HYPOCALCEMIA,NEONATAL HYPOCALCAEMIA,CALCIUM METABOLISM DISORDERS,"BONE, CALCIUM, MAGNESIUM AND PHOSPHORUS METABOLISM DISORDERS",10027433,10079308,10079306,10079308
25562,MYCOPHENOLATE MOFETIL AND RITUXIMAB USED FOR GRANULOMATOSIS WITH POLYANGIITIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
25673,FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
25744,PRIMARILY REFRACTORY/STABLE DISEASE/NO RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
25836,MITRAL MVP THROMBOSIS,Prosthetic cardiac valve thrombosis,PROSTHETIC CARDIAC VALVE THROMBOSIS,PROSTHETIC CARDIAC VALVE THROMBOSIS,CARDIAC VALVE DISORDERS NEC,CARDIAC VALVE DISORDERS,10007541,10063176,10063176,10063176
25859,DISTURBED DAY-NIGHT RHYTHM,Irregular sleep wake rhythm disorder,SLEEP PHASE RHYTHM DISTURBANCE,IRREGULAR SLEEP WAKE RHYTHM DISORDER,DISTURBANCES IN SLEEP PHASE RHYTHM,SLEEP DISTURBANCES (INCL SUBTYPES),10029205,10041003,10080301,10041003
25903,METHOTREXATE (MTX) ASSOCIATED EPSTEIN-BARR VIRUS-POSITIVE MUCOCUTANEOUS ULCER/SKIN ULCER,Epstein Barr virus positive mucocutaneous ulcer,EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER,EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER,LYMPHOPROLIFERATIVE DISORDERS NEC (EXCL LEUKAEMIAS AND LYMPHOMAS),HAEMATOPOIETIC NEOPLASMS (EXCL LEUKAEMIAS AND LYMPHOMAS),10029104,10079386,10079386,10079386
25988,DRUG USED FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26017,LIP ERYTHEMA,Lip erythema,LIP ERYTHEMA,LIP ERYTHEMA,ORAL SOFT TISSUE SIGNS AND SYMPTOMS,ORAL SOFT TISSUE CONDITIONS,10017947,10080124,10080124,10080124
26021,NOCTURAL SYMPTOMS AND OCCASIONAL FAECAL INCONTINENCE,Anal incontinence,FAECAL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10016092,10077605,10016092
26032,RE-OCCURRENCE OF SCINTILLATING SCOTOMA OF APPROXIMATELY 60 MIN DURATION COINCIDING WITH A PAIN EXACERBATION,Symptom recurrence,SYMPTOM RECURRENCE,SYMPTOM RECURRENCE,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10080080,10080080,10080080
26114,"DESPITE CONSERVATIVE TREATMENT, THE CONDITION OF HIS EYELID HAD NOT IMPROVED, SO HE RECEIVED A SUBCUTANEOUS TA INJECTION (4 MG/0.05 ML).",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26245,LITHIUM-INDUCED END STAGE RENAL DISEASE,end stage renal disease,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
26284,MULTI ORGAN FAILURE DUE TO DISSEMINATION OF ADENOVIRUS INFECTION FOLLOWING LACK OF DRUG EFFECT OF RIBAVIRIN,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
26297,AMOXICILLIN/CLAVULANIC ACID AND AZITHROMYCIN USED FOR NOCARDIOSIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26310,PEAK CORTISOL RESPONSE TO A LOW-DOSE (1UG)ACTH STIMULATION TEST WAS 18.7 UG/DL,Cortisol increased,CORTISOL INCREASED,CORTISOL INCREASED,ADRENAL CORTEX TESTS,ENDOCRINE INVESTIGATIONS (INCL SEX HORMONES),10022891,10011207,10011207,10011207
26318,TENOFOVIR DISOPROXIL FUMARATE- ASSOCIATED RENAL TUBULAR DYSFUNCTION,Renal tubular dysfunction,RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10050335,10050335,10050335
26342,HBV REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
26353,OESTROGENS AND FINASTERIDE PURCHASED ONLINE IN ORDER TO PROCEED WITH THE TRANSITION/FINASTERIDE USED FOR GENDER AFFIRMATION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
26427,DRUG EXPOSURE VIA BREAST MILK,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
26480,RITUXIMAB USED FOR TREATMENT OF MERKEL CELL CARCINOMA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26488,DID NOT SEEM TO CONTROL HER TUMOR-RELATED PAIN,therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
26553,INTRA-PLEURAL STREPTOKINASE INSTILLATION WAS GIVEN AT 12 HOURS TIME INTERVAL AS A ALTERNATIVE THERAPEUTIC OPTION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26631,METHOTREXATE USED FOR TREATMENT OF SARCOIDOSIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26749,REPETITIVE NERVE STIMULATION REVEALED DECREMENTAL RESPONSE OVER 10% AT 2-3 HZ. THE 6MWT BASELINE WAS 380 M AND SALBUTAMOL TREATMENT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
26828,DEPERSONALIZATION,depersonalization,DEPERSONALIZATION,DEPERSONALISATION/DEREALISATION DISORDER,DISSOCIATIVE STATES,DISSOCIATIVE DISORDERS,10037175,10012359,10077805,10012359
26850,COLOR VISION CHANGES,Dyschromatopsia,COLOR VISION CHANGE,DYSCHROMATOPSIA,COLOUR BLINDNESS (INCL ACQUIRED),VISION DISORDERS,10015919,10068918,10013892,10068914
26864,NORMOCYTIC ANEMIA,Normocytic anaemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029785
26866,SEXUAL HEADACHE,Primary headache associated with sexual activity,PRIMARY HEADACHE ASSOCIATED WITH SEXUAL ACTIVITY,PRIMARY HEADACHE ASSOCIATED WITH SEXUAL ACTIVITY,HEADACHES NEC,HEADACHES,10029205,10079056,10079056,10079056
26872,BILIARY DYSPEPSIA,biliary dyspepsia,BILIARY DYSPEPSIA,BILIARY DYSPEPSIA,HEPATOBILIARY SIGNS AND SYMPTOMS,HEPATIC AND HEPATOBILIARY DISORDERS,10019805,10077835,10077835,10077835
26903,PSYCHOORGANIC SYNDROME,Psychoorganic syndrome,PSYCHOORGANIC SYNDROME,ORGANIC BRAIN SYNDROME,MENTAL DISORDERS DUE TO A GENERAL MEDICAL CONDITION NEC,PSYCHIATRIC DISORDERS NEC,10037175,10078099,10031077,10078099
26912,EMERGENCE OF PSYCHOTIC SYMPTOMS,psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
27058,TUMEFACTIVE DEMYELINATING LESIONS,Tumefactive multiple sclerosis,TUMEFACTIVE MULTIPLE SCLEROSIS,TUMEFACTIVE MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS ACUTE AND PROGRESSIVE,DEMYELINATING DISORDERS,10029205,10078556,10078556,10078556
27071,OGILVIE SYNDROME,Ogilvie syndrome,OGILVIE'S SYNDROME,INTESTINAL PSEUDO-OBSTRUCTION,GASTROINTESTINAL ATONIC AND HYPOMOTILITY DISORDERS NEC,GASTROINTESTINAL MOTILITY AND DEFAECATION CONDITIONS,10017947,10052504,10022698,10052504
27136,AFTER CLOSE MONITORING WITH PT/OT/SLP IT WAS NOTED THAT THE PATIENT HADSIGNIFICANT IMPROVEMENT OF HER DYSTONIC MOVEMENTS IN ALL FOUR EXTREMITIES.,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
27150,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
27189,MULITPLE ORGAN FAILURE DUE TO SEPSIS,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
27218,THE MEDICATION PRESERVATION WAS NOT ADEQUATE. THE PHYSICAL-CHEMICAL CHARACTERISTICS OF THE TABLETS WERE PROBABLY AFFECTED,Product storage error,PRODUCT STORAGE ERROR,PRODUCT STORAGE ERROR,PRODUCT STORAGE ERRORS AND ISSUES IN THE PRODUCT USE SYSTEM,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10079843,10079843,10079843
27237,DOSE INCREASED,Wrong dose,ACCIDENTAL DOSE INCREASE,WRONG DOSE,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074988,10080304,10074988
27257,BITEMPORAL INFERIOR QUADRANTANOPIA (FOLLOWING FUNGAL ABSCESS),Quadrantanopia,QUADRANTANOPIA,QUADRANTANOPIA,NEUROLOGIC VISUAL PROBLEMS NEC,NEUROLOGICAL DISORDERS OF THE EYE,10029205,10077820,10077820,10077820
27310,CYCLOPHOSPHAMIDE AND DOXORUBICIN USED FOR FOLLICULOTROPIC SEZARY SYNDROME,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
27332,MENTALLY REDUCED,Intellectual disability,DEFICIENCY MENTAL,INTELLECTUAL DISABILITY,INTELLECTUAL DISABILITIES,MENTAL IMPAIRMENT DISORDERS,10029205,10027378,10067989,10012131
27380,AUTO-BREWERY SYNDROME,Auto-brewery syndrome,AUTO-BREWERY SYNDROME,GUT FERMENTATION SYNDROME,GASTROINTESTINAL DISORDERS NEC,GASTROINTESTINAL CONDITIONS NEC,10017947,10080603,10080594,10080603
27399,PARTIAL RESPONSE,Therapy partial responder,THERAPY PARTIAL RESPONDER,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10078115
27418,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS SYNDROME (GRADE 2),periarticular thenar erythema with onycholysis,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10078288,10078288,10078288
27441,PSYCHOTIC SYMPTOMS,Psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
27591,TOXIC ERYTHEMA OF CHEMOTHERAPY WITH BALANITIS AND GRADE 2 ACRAL ERYTHEMA,Toxic erythema of chemotherapy,TOXIC ERYTHEMA OF CHEMOTHERAPY,TOXIC ERYTHEMA OF CHEMOTHERAPY,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10074982,10074982,10074982
27626,REFUSAL OF FEEDS,Food refusal,FOOD REFUSAL,FOOD REFUSAL,APPETITE DISORDERS,APPETITE AND GENERAL NUTRITIONAL DISORDERS,10027433,10080283,10080283,10080283
27628,"CROSS REACTIVITY TO CEFACLOR, CEFADROXIL AND CEFALEXIN",Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
27664,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
27713,MOF,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
27836,"POOR RECALL AND IMPACT ON IADL PERFORMANCE, REQUIRING HELP WITH FINANCES AND MEDICATION MANAGEMENT",Loss of personal independence in daily activities,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10079487,10079487,10079487
27881,ORBITAL COMPARTMENT SYNDROME DUE TO HYALURONIDASE ALLERGY,Orbital compartment syndrome,ORBITAL COMPARTMENT SYNDROME,ORBITAL COMPARTMENT SYNDROME,OCULAR BLEEDING AND VASCULAR DISORDERS NEC,OCULAR HAEMORRHAGES AND VASCULAR DISORDERS NEC,10015919,10079161,10079161,10079161
27891,CENTRAL BRADYCARDIA,central bradycardia,CENTRAL BRADYCARDIA,CENTRAL BRADYCARDIA,RATE AND RHYTHM DISORDERS NEC,CARDIAC ARRHYTHMIAS,10007541,10078310,10078310,10078310
27917,CYTARABINE AND CELECOXIB USED FOR ATYPICAL TERATOID RHABDOID TUMOR GRADE IV,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
27955,LEVELS OF ANTI-XA ACTIVITY REDUCED,Anti factor Xa activity decreased,ANTI FACTOR XA ACTIVITY DECREASED,ANTI FACTOR XA ACTIVITY DECREASED,COAGULATION AND BLEEDING ANALYSES,HAEMATOLOGY INVESTIGATIONS (INCL BLOOD GROUPS),10022891,10078931,10078931,10078931
27968,NEONATAL RESPIRATORY DISTRESS,Neonatal respiratory distress,NEONATAL RESPIRATORY DISTRESS,NEONATAL RESPIRATORY DISTRESS,NEONATAL HYPOXIC CONDITIONS,NEONATAL RESPIRATORY DISORDERS,10038738,10028973,10028973,10028973
28007,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
28125,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS SYNDROME (GRADE 2)/GRADE II PERIARTICULAR THENAR ERYTHEMA AND ONYCHOLYSIS SYNDROME,Periarticular thenar erythema with onycholysis,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS,PERIARTICULAR THENAR ERYTHEMA WITH ONYCHOLYSIS,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10078288,10078288,10078288
28233,DEXAMETHASONE USED TO TREAT INFLUENZA B VIRUS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
28245,MULTI-ORGAN FAILURE DUE TO HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
28254,REACTIVATION OF HEPATITIS B VIRUS,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
28275,"THE SEIZURES FREQUENCY AND DURATION WERE REDUCED AS WELL AS THE NUCHAL RIGIDITY, FLAT BOARD, AND TRISMUS WERE IMPROVED.",Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
28330,CARVEDILOL CONTRAINDICATED IN PATIENTS WITH LIVER DYSFUNCTION,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
28389,FREE FLUID IN ABDOMINAL PELVIC CAVITY,Intra-abdominal fluid collection,INTRA-ABDOMINAL FLUID COLLECTION,INTRA-ABDOMINAL FLUID COLLECTION,PERITONEAL AND RETROPERITONEAL DISORDERS,PERITONEAL AND RETROPERITONEAL CONDITIONS,10017947,10078659,10078659,10078659
28442,OVER SEDATION,Sedation complication,OVERSEDATION,SEDATION COMPLICATION,ANAESTHETIC AND ALLIED PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10033305,10079741,10033305
28461,REFRACTORY GRAFT-VERSUS-HOST DISEASE,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
28513,POSTPRANDIAL HYPOGLYCAEMIA (GLUCOSE BETWEEN 2.3 AND 4.2 MMOL/L),Postprandial hypoglycaemia,POSTPRANDIAL HYPOGLYCAEMIA,POSTPRANDIAL HYPOGLYCAEMIA,HYPOGLYCAEMIC CONDITIONS NEC,GLUCOSE METABOLISM DISORDERS (INCL DIABETES MELLITUS),10027433,10059035,10059035,10059035
28527,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
28629,NO RESPONSE TO TREATMENT WITH OPIOIDS AND ANTI-HYPERTENSION MEDICATIONS,no therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
28648,SCLEROSING ESOPHAGITIS WITH IGG4-POSITIVE PLASMA CELL INFILTRATION,Immunoglobulin G4 related disease,IMMUNOGLOBULIN G4 RELATED DISEASE,IMMUNOGLOBULIN G4 RELATED DISEASE,CONNECTIVE TISSUE DISORDERS NEC,CONNECTIVE TISSUE DISORDERS (EXCL CONGENITAL),10028395,10077271,10077271,10077271
28690,HYDROXYCHLOROQUINE AND MYCOPHENOLATE USED FOR DERMATOMYOSITIS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
28702,MILD LV DILATION,Left ventricular dilatation,LEFT VENTRICULAR DILATATION,LEFT VENTRICULAR DILATATION,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10050043,10050043,10050043
28738,NOT ABLE TO MOVE OR WALK INDEPENDENTLY FOR THE LAST 5 MONTHS,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
28758,SPRUE-LIKE ENTEROPATHY ASSOCIATED TO TAKING OLMESARTAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
28760,NECROTIZING GRANULOMATOUS INFLAMMATION/LYMPHADENITIS,Granulomatous lymphadenitis,NECROTIZING GRANULOMATOUS LYMPHADENITIS,GRANULOMATOUS LYMPHADENITIS,LYMPHATIC SYSTEM DISORDERS NEC,"SPLEEN, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEM DISORDERS",10005329,10058540,10078494,10058550
28846,JOINT CREPITATION,Joint crepitation,JOINT CREPITATION,JOINT NOISE,JOINT RELATED SIGNS AND SYMPTOMS,JOINT DISORDERS,10028395,10051374,10074329,10051374
28955,"PATIENT REQUIRED PREDNISONE, NAPROXEN, CHLOROQUIN DURING BREAST-FEEDING (EXPOSURE DURING BREAST FEEDING WITH NO ADR)",Maternal exposure during breast feeding,EXPOSURE DURING BREAST FEEDING,MATERNAL EXPOSURE DURING BREAST FEEDING,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10071402,10080752,10071402
29068,MUTLIPLE ORGAN FAILURE FOLLOWING TUBERCULOUS MENINGOCEPHALITIS,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
29276,FIXED DRUG ERUPTION DUE TO FLUCONAZOLE,fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
29294,FUROSEMIDE TAKEN FOR WEIGHT LOSS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
29346,"USED FOR COUGH,WITH SUBJECTIVE IMPROVEMENT ALMOST IMMEDIATELY AND ABILITY TO SLEEP FOR HOURS UNINTERRUPTED",Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
29366,BACLOFEN USED FOR HYPOMYELINATING DISORDER,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
29376,FOLIC ACID TAKEN FOR SEROPOSITIVE RHEUMATOID ARTHRITIS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
29396,MULTIPLE ORGAN FAILURE,multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
29415,PROCEDURAL PNEUMOTHORAX,procedural pneumothorax,PROCEDURAL PNEUMOTHORAX,PROCEDURAL PNEUMOTHORAX,CARDIAC AND VASCULAR PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10077574,10077574,10077574
29474,HEPATITIS B REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
29517,LOSS OF AMBULATION,Unable to walk,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10049278,10017581,10049278
29533,OGILVIE'S SYNDROME,Intestinal pseudo-obstruction,OGILVIE'S SYNDROME,INTESTINAL PSEUDO-OBSTRUCTION,GASTROINTESTINAL ATONIC AND HYPOMOTILITY DISORDERS NEC,GASTROINTESTINAL MOTILITY AND DEFAECATION CONDITIONS,10017947,10052504,10022698,10052504
29539,"ADJUSTED SERUM CALCIUM (CA), INTACT - PARATHYROID HORMONE (I-PTH) INCREASED TO EQUAL TO OR MORE THAN REFERENCE VALUE/ADJUSTED CALCIUM INCREASED/21.0",Adjusted calcium increased,ADJUSTED CALCIUM INCREASED,ADJUSTED CALCIUM INCREASED,MINERAL AND ELECTROLYTE ANALYSES,"WATER, ELECTROLYTE AND MINERAL INVESTIGATIONS",10022891,10078260,10078260,10078260
29579,FIXED DRUG ERUPTION,fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
29620,HEPATITIS B VIRUS REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
29627,GABAPENTIN USED FOR NEURALGIC AMYOTROPHY,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
29681,MYCOPHENOLATE MOFETIL FOR MASSIVE PNEUMONITIS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
29722,COMPLETE RESPONSE AFTER SIX CYCLES OF IRINOTECAN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
29793,CONTINUED TAKING PREGABALIN 200MG TID WITH ONLY MODEST PAIN REDUCTION,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
29925,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
29983,EPSTEIN-BARR-VIRUS-RELATED MUCOCUTANEOUS ULCERATION WITH EXPRESSION OF CD30 AND CD45,Epstein Barr virus positive mucocutaneous ulcer,EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER,EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER,LYMPHOPROLIFERATIVE DISORDERS NEC (EXCL LEUKAEMIAS AND LYMPHOMAS),HAEMATOPOIETIC NEOPLASMS (EXCL LEUKAEMIAS AND LYMPHOMAS),10029104,10079386,10079386,10079386
30070,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
30106,FUROSEMIDE TAKEN FOR WEIGHT LOSS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
30144,BLACK VOMITING,Discoloured vomit,DARK COLOUR VOMITING,DISCOLOURED VOMIT,NAUSEA AND VOMITING SYMPTOMS,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10075321,10079120,10075321
30228,CALCIPHYLAXIS DID NOT IMPROVE,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
30264,BENIGN INTRACRANIAL HYPERTENSION LEADING TO VISUAL LOSS,Idiopathic intracranial hypertension,BENIGN INTRACRANIAL HYPERTENSION,IDIOPATHIC INTRACRANIAL HYPERTENSION,INCREASED INTRACRANIAL PRESSURE DISORDERS,INCREASED INTRACRANIAL PRESSURE AND HYDROCEPHALUS,10029205,10004277,10078904,10004277
30289,MASSIVE THROMBOSIS OF I.V. PORT,catheter related thrombosis,CATHETER RELATED THROMBOSIS,DEVICE RELATED THROMBOSIS,VASCULAR COMPLICATIONS ASSOCIATED WITH DEVICE,COMPLICATIONS ASSOCIATED WITH DEVICE,10018065,10077456,10077455,10077456
30327,LOW DOSE ASPIRIN GIVEN FOR SLE,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
30396,LACK OF REMISSION FOLLOWING PREVIOUS THERAPIES,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
30508,NOT PREVENTING PALPITATIONS WHICH OCCURED NEARLY DAILY BOTH AT REST AND EXERCISE,no therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
30541,LIMITING HER ABILITY TO PERFORM INSTRUMENTAL ADLS,activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
30679,MULTI ORGAN FAILURE FOLLOWING STAPHYLOCOCCAL TOXIC SHOCK SYNDROME,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
30692,ACTIVITIES OF DAILY LIVING IMPAIRED,Loss of personal independence in daily activities,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
30818,NON-CIRRHOTIC PORTAL HYPERTENSION,Non-cirrhotic portal hypertension,NON-CIRRHOTIC PORTAL HYPERTENSION,NON-CIRRHOTIC PORTAL HYPERTENSION,HEPATIC VASCULAR DISORDERS,HEPATIC AND HEPATOBILIARY DISORDERS,10019805,10077259,10077259,10077259
30857,"CATAFLAM WAS USED FOR FEVER, THRILL, CHILLS",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
30893,NEUROPSYCHIATRIC COMPLAINTS,neuropsychiatric symptoms,NEUROPSYCHIATRIC SYMPTOMS,NEUROPSYCHIATRIC SYMPTOMS,MENTAL DISORDERS DUE TO A GENERAL MEDICAL CONDITION NEC,PSYCHIATRIC DISORDERS NEC,10037175,10078497,10078497,10078497
30906,"THERE WAS A GOOD RESPONSE OF ATTACKS TO IBUPROFEN, WHICH NO LONGER HAPPENS/ NO RESPONSE",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
31098,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
31141,HIV-1 PERSISTENT VIREMIA FOLLOWING DRUG RESISTANCE DUE TO M46IM MUTATION,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
31185,FENTANYL USED FOR CONTROLLING HER DEPOSITIONS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
31199,LATE HBV REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
31375,END-STAGE LIVER DISEASE (MELD) SCALE PROGRESSIVELY WORSENED TO 34,MELD score abnormal,MELD SCORE ABNORMAL,MODEL FOR END STAGE LIVER DISEASE SCORE ABNORMAL,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077293,10077291,10077293
31377,ULCERS ON BOTH PALATINE PILLARS,palatal ulcer,PALATAL ULCER,PALATAL ULCER,STOMATITIS AND ULCERATION,ORAL SOFT TISSUE CONDITIONS,10017947,10077519,10077519,10077519
31386,BLEOMYCIN ADMINISTERED TO PATIENT WITH POOR RESPIRATORY FUNCTION SECANDARY TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
31441,MASK LIKE FACE,Mask like facies,MASK LIKE FACIES,REDUCED FACIAL EXPRESSION,PARKINSON'S DISEASE AND PARKINSONISM,MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10026861,10078576,10026861
31461,HIGH JOHN CUNNINGHAM VIRUS (JCV) ANTIBODY INDEX,JC polyomavirus test positive,JC VIRUS TEST POSITIVE,JC POLYOMAVIRUS TEST POSITIVE,VIRUS IDENTIFICATION AND SEROLOGY,MICROBIOLOGY AND SEROLOGY INVESTIGATIONS,10022891,10068795,10070356,10068795
31515,FAILED TO RESPOND,therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
31533,NO RESPONSE TO LIPID-LOWERING THERAPY,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
31627,NO CLINICAL RESPONSE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
31662,"ATRIAL FIBRILLATION PERSISTED DESPITE AMIODARONE,",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
31664,PATIENT DID NOT IMPROVE,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
31696,AMIODARONE-INDUCED CORNEA VERTICILLATA/ AMIODARONE-INDUCED VORTEX KERATOPATHY/ AMIODARONE KERATOPATHY,Cornea verticillata,CORNEA VERTICILLATA,CORNEA VERTICILLATA,"CORNEAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION","ANTERIOR EYE STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION",10015919,10077604,10077604,10077604
31715,HYPOCORTISOLISM,cortisol decreased,CORTISOL DECREASED,CORTISOL DECREASED,ADRENAL CORTEX TESTS,ENDOCRINE INVESTIGATIONS (INCL SEX HORMONES),10022891,10011198,10011198,10011198
31717,"WORSENING OF TALAROMYCES (PENICILLIUM) MARNEFFEI FOLLOWING LIPOSOMAL AMPHOTERICIN B, VORICONAZOLE AND MICAFUNGIN",Penicillium infection,PENICILLIUM INFECTION,PENICILLIUM INFECTION,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10078580,10078580,10078580
31792,RUXOLITINIB FOR THE TREATMENT OF CORTICOSTEROID REFRACTORY GRAFT VERSUS HOST DISEASE,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
31800,METHOTREXATE USED FOR TREATMENT OF SARCOIDOSIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
31805,"MULTI-ORGAN DYSFUNCTION WITH RENAL, RESPIRATORY, AND HEPATIC FAILURE FOLLOWING LACK OF DRUG EFFECT",multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
31841,CONATIVE FUNCTION DEFICITS AND ACTIVITIES OF DAILY LIVING DEPENDENCY,activities of daily living impairment,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
31902,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
31940,FACIAL PARALYSIS,Facial paralysis,FACIAL PARALYSIS,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016062
31953,OLMESARTAN-INDUCED ENTEROCOLOPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
31996,MULTIORGAN FAILURE,Multiorgan failure,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028162,10077361,10028162
32032,KERATITIS HAD BEEN TREATED WITH MINOCYCLINE (DRUG USE FOR UNAPPROVED INDICATION WITH NO ADR),Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
32174,ECHOGENIC BOWEL,Fetal gastrointestinal tract imaging abnormal ,FETAL GASTROINTESTINAL TRACT IMAGING ABNORMAL,FOETAL GASTROINTESTINAL TRACT IMAGING ABNORMAL,FOETAL AND NEONATAL IMAGING PROCEDURES,FOETAL AND NEONATAL INVESTIGATIONS,10022891,10077587,10077579,10077587
32246,CONTRAINDICATED DRUG ADMINISTERED,contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
32261,MINERALOCORTICOID EXCESS SYNDROME,Acquired apparent mineralocorticoid excess,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ADRENAL CORTICAL HYPERFUNCTIONS,ADRENAL GLAND DISORDERS,10014698,10080230,10080230,10080230
32300,PATIENT WAS TREATED WITH DIVALPROEX SODIUM FOR ABDOMINAL MIGRAINE AND IT RELIEVED THE SYMPTOMS,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
32325,"MYCOPHENOLATE MOFETIL, METHOTREXATE USED FOR TREATMENT OF PUK",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
32336,PREDNISONE AND MYCOPHENOLATE MOFETIL FOR PANCREAS ALLOGRAFT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
32401,SPRUE-LIKE ENTEROPATHY ASSOCIATED WITH TAKING OLMESARTAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
32484,DYSMETRIA,dysmetria,DYSMETRIA,DYSMETRIA,COORDINATION AND BALANCE DISTURBANCES,NEUROLOGICAL DISORDERS NEC,10029205,10013936,10013936,10013936
32499,MYCOPHENOLATE MOFETIL AND METHYLPREDNISOLONE USED IN UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
32575,COULD NOT WALK INDEPENDENTLY,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
32612,IMIPENEM/CILASTATIN WAS USED FOR MYCOBACTERIUM ABSCESSUS MENINGEAL INFECTION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
32636,PATIENT RECEIVED NIMODIPIN FOR ARTERIAL VASODILATION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
32761,MULTIPLE ORGAN DYSFUNCTION SYNDROME,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
32771,SMALL INTESTINAL BACTERIAL OVERGROWTH SYNDROME,Gastrointestinal bacterial overgrowth,SMALL INTESTINAL BACTERIAL OVERGROWTH,GASTROINTESTINAL BACTERIAL OVERGROWTH,BACTERIAL INFECTIONS NEC,BACTERIAL INFECTIOUS DISORDERS,10021881,10071061,10078158,10071061
32836,CUTANEOUS PHAEOHYPHOMYCOSIS,phaeohyphomycosis,PHAEOHYPHOMYCOSIS,PHAEOHYPHOMYCOSIS,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10080815,10080815,10080815
32936,HEPATITIS B VIRUS INFECTION REACTIVATION/ VIROLOGICAL REACTIVATION OF HEPATITIS B VIRUS INFECTION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
32982,A 4-MONTH-OLD HISPANIC BOY TREATED WITH PROPRANOLOL,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
33109,INTENTIONAL USE FOR UNLABELED INDICATION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
33167,REQUIRED ASSISTANCE WITH ALL HIS ACTIVITIES OF DAILY LIVING (ADLS),activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
33249,MULTIPLE ORGAN FAILURE DUE TO LACTIC ACIDOSIS,multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
33274,SPRUE-LIKE ENTEROPATHY/DRUG-INDUCED ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
33336,DRUG CROSS-REACTIVITY,Drug cross-reactivity,DRUG CROSS-REACTIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10076743,10079645,10076743
33344,BOWEL  INCONTINENCE,Bowel incontinence,BOWEL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10050492,10077605,10050492
33346,NO RESPONSE,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
33403,INITIATION OF AMIODARONE FOR ATRIAL FIBRILLATION,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
33538,SUSPECTED INDUCTION OF PSYCHOTIC SYMPTOMS,psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
33540,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
33596,INCREASED FRUSTRATION,Frustration,FRUSTRATION,FRUSTRATION TOLERANCE DECREASED,EMOTIONAL AND MOOD DISTURBANCES NEC,MOOD DISORDERS AND DISTURBANCES NEC,10037175,10064862,10077753,10064862
33636,SPRUE-LIKE ENTEROPATHY DURING TREATMENT WITH OLMESARTAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
33639,LEVELS OF ANTI XA ACTIVITY REDUCED,Anti factor Xa activity decreased,ANTI FACTOR XA ACTIVITY DECREASED,ANTI FACTOR XA ACTIVITY DECREASED,COAGULATION AND BLEEDING ANALYSES,HAEMATOLOGY INVESTIGATIONS (INCL BLOOD GROUPS),10022891,10078931,10078931,10078931
33733,BACTERIAL PNEUMONIA (ACINETOBACTER BAUMANNII),Pneumonia acinetobacter,PNEUMONIA ACINETOBACTER,PNEUMONIA ACINETOBACTER,BACTERIAL INFECTIONS NEC,BACTERIAL INFECTIOUS DISORDERS,10021881,10079866,10079866,10079866
33738,"FAILED TO RESPOND TO NUMEROUS PSYCHIATRIC MEDICATIONS, AS WELL AS COMBINATIONS OF THESE",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
33757,NIFEDIPINE GIVEN AT 31 + 1 WEEKS OF GESTATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
33810,END STAGE RENAL DISESASE,end stage renal disesase,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
33867,ABIRATERONE-INDUCED MINERALOCORTICOID EXCESS SYNDROME,Acquired apparent mineralocorticoid excess,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ACQUIRED APPARENT MINERALOCORTICOID EXCESS,ADRENAL CORTICAL HYPERFUNCTIONS,ADRENAL GLAND DISORDERS,10014698,10080230,10080230,10080230
33879,PARTIAL THERAPEUTIC RESPONSE,Therapy partial responder,THERAPY PARTIAL RESPONDER,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10078115
33932,COMPLEX PARTIAL EPILEPTIC ATTACK,Focal dyscognitive seizures,COMPLEX PARTIAL SEIZURES,FOCAL DYSCOGNITIVE SEIZURES,PARTIAL COMPLEX SEIZURES,SEIZURES (INCL SUBTYPES),10029205,10010145,10079424,10010145
33961,ADMITTED TO THE SUBSTANCE-ABUSE TREATMENT WARD FOR OPIOID ADDICTION,opioid use disorder,OPIOID USE DISORDER,DRUG USE DISORDER,SUBSTANCE RELATED AND ADDICTIVE DISORDERS,PSYCHIATRIC DISORDERS NEC,10037175,10079385,10079381,10079385
33963,PATIENT RECEIVED ASPIRIN DURING PREGNANCY,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
34055,PARTIAL RESPONSE,Therapy partial responder,THERAPY PARTIAL RESPONDER,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10078115
34198,DEXAMETHASONE USED TO TREAT INFLUENZA B VIRUS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
34230,DYSMETRIA,dysmetria,DYSMETRIA,DYSMETRIA,COORDINATION AND BALANCE DISTURBANCES,NEUROLOGICAL DISORDERS NEC,10029205,10013936,10013936,10013936
34249,METHOTREXATE USED FOR TREATMENT OF SARCOIDOSIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
34298,GRANULOMATOUS INFLAMMATION,Granulomatous lymphadenitis,GRANULOMATOUS LYMPHADENITIS,GRANULOMATOUS LYMPHADENITIS,LYMPHATIC SYSTEM DISORDERS NEC,"SPLEEN, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEM DISORDERS",10005329,10078494,10078494,10078494
34366,CARCINOMA OF DESCENDING COLON,Intestinal metastasis,METASTASES TO LARGE INTESTINE,INTESTINAL METASTASIS,METASTASES TO SPECIFIED SITES,METASTASES,10029104,10027456,10080311,10027456
34500,OESOPHAGEAL INTRAMURAL HAEMATOMA,Oesophageal intramural haematoma,OESOPHAGEAL INTRAMURAL HAEMATOMA,OESOPHAGEAL INTRAMURAL HAEMATOMA,GASTRIC AND OESOPHAGEAL HAEMORRHAGES,GASTROINTESTINAL HAEMORRHAGES NEC,10017947,10077486,10077486,10077486
34518,"PATIENT WAS PRESCRIBED PENTOXIFYLLINE, 400",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
34524,THESE MEASURES RESULTED IN MINIMAL IMPROVEMENT,Partial responder to therapy,PARTIAL RESPONDER TO THERAPY,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10066429,10078115,10066429
34560,NO THERAPEUTIC RESPONSE/RECURRENCE OF ATRIAL FLUTTER TWO MONTHS AFTER AN ELECTRICAL CARDIOVERSION AND DESPITE A LONG-TERM PREVENTIVE TREATMENT WITH AMIODARONE,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
34583,POST MORTEM BLOOD REVEALED DIPHENHYDRAMINE LEVEL TO BE 8.5 MCG/ML,Postmortem blood drug level increased,POSTMORTEM BLOOD DRUG LEVEL INCREASED,POSTMORTEM BLOOD DRUG LEVEL INCREASED,TOXICOLOGY LABORATORY ANALYSES,TOXICOLOGY AND THERAPEUTIC DRUG MONITORING,10022891,10078489,10078489,10078489
34607,OLMESARTAN-INDUCED SPRUE-LIKE ENTEROCOLOPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
34660,FIXED DRUG ERUPTION ASSOCIATED WITH PARACETAMOL INGESTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
34690,REACTIVATION OF HEPATITIS B,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
34693,RIVAROXABAN USED FOR SPLANCHNIC VEIN THROMBOSIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
34721,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
34748,"RETAIN OF PAIN (POSSIBLE LACK OF EFFICACY), OFF LABEL USE (FOR CARBAMAZEPINE)",product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
34764,SEVERE MULTIPLE ORGAN FAILURE FOLLOWING METFORMIN-ASSOCIATED LACTIC ACIDOSIS,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
34826,MULTIORGAN FAILURE DUE TO SEVERE PNEUMONIA,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
34830,EOSINOPHILIC GRANULOMATOUS VASCULITIS,Eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOUS VASCULITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10014957,10078117,10014957
34971,REMISSION WITH TOPIRAMATE,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
34997,PRODUCT USE IN UNAPPROVED INDICATION,product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
35024,INTENTIONAL DOSE OMISSION,Intentional dose omission,INTENTIONAL DOSE OMISSION,INTENTIONAL DOSE OMISSION,INTENTIONAL PRODUCT USE ISSUES,OFF LABEL USES AND INTENTIONAL PRODUCT MISUSES/USE ISSUES,10022117,10079221,10079221,10079221
35029,PROGRESSION OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS FOLLOWING INADEQUATE TREATMENT,Eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10078117,10078117,10078117
35052,PROGRESS OF CKD STAGE 4 TO 5 DUE TO RITUXIMAB AND MYCOPHENOLATE MOFETIL USED FOR FOCAL SEGMENTAL GLOMERULAR SCLEROSIS (DRUG USE FOR UNAPPROVED INDICATION),Chronic kidney disease stage 5,CHRONIC KIDNEY DISEASE STAGE 5,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10076412,10077512,10076412
35066,ULCERS ON BOTH PALATINE PILLARS,palatal ulcer,PALATAL ULCER,PALATAL ULCER,STOMATITIS AND ULCERATION,ORAL SOFT TISSUE CONDITIONS,10017947,10077519,10077519,10077519
35119,SUSPECT DRUGS USED FOR JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
35164,PACLITAXEL USED FOR ANGIOMATOSIS,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
35201,LESIONS IN THE NOSE AND NASOLABIAL REGION,nose injury,NOSE INJURY,NASAL INJURY,SITE SPECIFIC INJURIES NEC,INJURIES NEC,10022117,10054854,10078651,10054854
35234,MULTIORGAN FAILURE FOLLOWING GASTROINTESTINAL HISTOPLASMOSIS (ILEO-COLONIC HISTOPLASMOSIS),Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
35334,ADVANCED EMPD THAT WERE SUCCESSFULLY CONTROLLED BY DOCETAXEL WITH CISPLATIN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
35375,DRUG INTERACTION BETWEEN ASPIRIN AND CLOPIDOGREL,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
35383,MULTI-ORGAN FAILURE,Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
35423,DRUG EXPOSURE VIA BREAST MILK,Drug exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
35425,COMPLEX PARTIAL TYPE EPILEPTIC SEIZURES,Complex partial seizures,COMPLEX PARTIAL SEIZURES,FOCAL DYSCOGNITIVE SEIZURES,PARTIAL COMPLEX SEIZURES,SEIZURES (INCL SUBTYPES),10029205,10010145,10079424,10010145
35504,MULTIORGAN FAILURE FOLLOWING STEVENS-JOHNSON SYNDROME (SJS)/TOXIC EPIDERMAL NECROLYSIS (TEN),Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
35514,PRODUCT USE IN UNAPPROVED INDICATION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
35563,TYPE 1 AUTOIMMUNE PANCREATITIS (AIP) WITH EXOCRINE INSUFFICIENCY,Pancreatic failure,PANCREATIC EXOCRINE INSUFFICIENCY,PANCREATIC FAILURE,PANCREATIC DISORDERS NEC,EXOCRINE PANCREAS CONDITIONS,10017947,10073392,10079281,10073392
35594,FIXED DRUG ERUPTION PARACETAMOL,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
35612,CRITICAL ILLNESS POLYNEUROPATHY,Critical illness polyneuropathy,CRITICAL ILLNESS POLYNEUROPATHY,INTENSIVE CARE UNIT ACQUIRED WEAKNESS,ACUTE POLYNEUROPATHIES,PERIPHERAL NEUROPATHIES,10029205,10066336,10077255,10066336
35718,MULTIPLE ORGAN DYSFUNCTION SYNDROME FOLLOWING SEPTIC SHOCK DUE TO ARDS AND INFLUENZA A H1N1 PNEUMONIA,Multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
35731,"SEIZURES PERSISTED DESPITE TREATMENT WITH PHENOBARBITAL,LEVETIRACETAM, LORAZEPAM, CLONAZEPAM, PYRIDOXINE, AND FOLINIC ACID.",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
35765,MULTIPLE ORGAN FAILURE FOLLOWING SEPTIC SHOCK DUE TO TOXIC AGRANULOCYTOSIS,multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
35815,DEVELOPED POST-TREATMENT LYME DISEASE SYNDROME AFTER COMPLETION OF ANTIBIOTIC THERAPY,Post treatment Lyme disease syndrome,POST TREATMENT LYME DISEASE SYNDROME,POST TREATMENT LYME DISEASE SYNDROME,BORRELIAL INFECTIONS,BACTERIAL INFECTIOUS DISORDERS,10021881,10079060,10079060,10079060
35854,TRANSMAMMARY EXPOSURE TO METHADONE,transmammary exposure to methadone,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
35908,KERATIC PRECIPITATES,keratic precipitates,KERATIC PRECIPITATES,KERATIC PRECIPITATES,"CORNEAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION","ANTERIOR EYE STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION",10015919,10053703,10053703,10053703
35925,HIV-1 PERSISTENT VIREMIA,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
36011,NON-KETOSIS HYPEROSMOLAR STATE FOLLOWING PENTAMIDINE-INDUCED DIABETES MELLITUS,Hyperglycaemic hyperosmolar nonketotic syndrome,HYPEROSMOLAR NON-KETOTIC HYPERGLYCAEMIA,HYPERGLYCAEMIC HYPEROSMOLAR NONKETOTIC SYNDROME,DIABETIC COMPLICATIONS NEUROLOGICAL,DIABETIC COMPLICATIONS,10027433,10079762,10063554,10079762
36066,MASKED FACE,Masked face,MASKED FACE,REDUCED FACIAL EXPRESSION,PARKINSON'S DISEASE AND PARKINSONISM,MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10026862,10078576,10026862
36097,ARIPIPRAZOLE USED FOR TREATMENT OF MAJOR DEPRESSION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
36112,WRONG PRODUCT STORED,Wrong product stored,WRONG PRODUCT STORED,WRONG PRODUCT STORED,PRODUCT STORAGE ERRORS AND ISSUES IN THE PRODUCT USE SYSTEM,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10080001,10080001,10080001
36160,REM BEHAVIOR DISORDER,REM sleep behavior disorder,REM SLEEP BEHAVIOR DISORDER,RAPID EYE MOVEMENT SLEEP BEHAVIOUR DISORDER,PARASOMNIAS,SLEEP DISORDERS AND DISTURBANCES,10037175,10078725,10077299,10078725
36169,DRAMATIC IMPACT ON HER FUNCTIONAL INDEPENDENCE,Loss of personal independence in daily activities,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10079487,10079487,10079487
36185,"TREATMENT WAS SHIFTED TO ANOTHER SODIUM CHANNEL BLOCKER, FLECAINIDE,",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
36218,HYDROXYCHLOROQUINE SULFATE USED FOR TREATMENT OF PULMONARY HEMOSIDEROSIS (UNAPPROVED INDICATION),Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
36223,"ULTRASONOGRAPHY OF ABDOMEN SUGGESTED GASEOUS ABDOMEN, FREE FLUID IN ABDOMEN, EDEMATOUS AND 9TO10MM THICKENED WALL OF ASCENDING COLON, TRANSVERSE COLON,DESCENDING COLON,SIGMOID COLON",Intra-abdominal fluid collection,INTRA-ABDOMINAL FLUID COLLECTION,INTRA-ABDOMINAL FLUID COLLECTION,PERITONEAL AND RETROPERITONEAL DISORDERS,PERITONEAL AND RETROPERITONEAL CONDITIONS,10017947,10078659,10078659,10078659
36290,"FLUDARABINE, IDARUBICIN AND G-CSF USED FOR MYELOID SARCOMA",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
36354,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
36391,DRUG EXPOSURE VIA LACTATION WITH NO ADR,exposure via breast milk,EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080751,10080751,10080751
36428,HBV REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
36434,LEFT VENTRICULAR DILATION,Left ventricular dilatation,LEFT VENTRICULAR DILATATION,LEFT VENTRICULAR DILATATION,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10050043,10050043,10050043
36455,PIROXICAM-INDUCED FIXED DRUG ERUPTION,fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
36639,HIV 1 PERSISTENT VIREMIA,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
36680,THERAPY NON-RESPONDER,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
36760,PREDNISONE USED FOR ERYTHEMA NODOSUM LEPROSUM,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
36790,PHAEOHYPHOMYCOSIS DUE TO ALTERNARIA ALTERNATA,Phaeohyphomycosis,PHAEOHYPHOMYCOSIS,PHAEOHYPHOMYCOSIS,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10080815,10080815,10080815
36792,FLUCLOXACILLIN FOR CHRONIC FOLLICULOCENTRIC PUSTULOSIS OF THE SCALP,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
36794,SINUS PAIN,Sinus pain,SINUS PAIN,SINUS PAIN,UPPER RESPIRATORY TRACT SIGNS AND SYMPTOMS,RESPIRATORY TRACT SIGNS AND SYMPTOMS,10038738,10040747,10040747,10040747
36993,CARDIAC DYSFUNCTION,cardiac dysfunction,CARDIAC DYSFUNCTION,CARDIAC DYSFUNCTION,CARDIAC DISORDERS NEC,CARDIAC DISORDER SIGNS AND SYMPTOMS,10007541,10079751,10079751,10079751
37018,END STAGE RENAL DISESASE,end stage renal disesase,END STAGE RENAL DISEASE,END STAGE RENAL DISEASE,RENAL FAILURE AND IMPAIRMENT,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10077512,10077512,10077512
37060,TONGUE ERYTHEMA,Tongue erythema,TONGUE ERYTHEMA,TONGUE ERYTHEMA,TONGUE SIGNS AND SYMPTOMS,TONGUE CONDITIONS,10017947,10079075,10079075,10079075
37098,UNABLE TO WALK,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
37131,SOUTHERN TICK-ASSOCIATED RASH ILLNESS,Southern tick-associated rash illness,SOUTHERN TICK-ASSOCIATED RASH ILLNESS,SOUTHERN TICK-ASSOCIATED RASH ILLNESS,INFECTIONS NEC,INFECTIONS - PATHOGEN UNSPECIFIED,10021881,10079029,10079029,10079029
37135,GENERALIZED BULLOUS FIXED DRUG ERUPTION (GBFDE),Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
37183,TABLET BACLOFEN 20 MG PER DAY WAS STARTED AS AN ANTI-CRAVING AGENT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
37226,MULTIPLE ORGAN FAILURE FOLLOWING HISTOPLASMA CAPSULATUM INFECTION,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
37233,PULMONARY NOCARDIOSIS,Pulmonary nocardiosis,PULMONARY NOCARDIOSIS,PULMONARY NOCARDIOSIS,NOCARDIA INFECTIONS,BACTERIAL INFECTIOUS DISORDERS,10021881,10080435,10080435,10080435
37251,"NORMOCYTIC ANEMIA (RBC 3.4 M, HGB 10.9 G/DL, HCT 32.7%, MCV 96 FL, MCH 31.8 PG,)",Normocytic anemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029785,10029784,10029785
37282,HYPOMIMIA,Reduced facial expression,REDUCED FACIAL EXPRESSION,REDUCED FACIAL EXPRESSION,PARKINSON'S DISEASE AND PARKINSONISM,MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10078576,10078576,10078576
37308,"SPINE COMPRESSION AT T8,10, 12 AND L5",Spinal flattening,LUMBAR SPINE FLATTENING,SPINAL FLATTENING,SPINE AND NECK DEFORMITIES,MUSCULOSKELETAL AND CONNECTIVE TISSUE DEFORMITIES (INCL INTERVERTEBRAL DISC DISORDERS),10028395,10051823,10077756,10051823
37328,RETINA THICKENED DUE TO OCULAR LYMPHOMA,Retinal thickening,RETINAL THICKENING,RETINAL THICKENING,"RETINAL STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION","OCULAR STRUCTURAL CHANGE, DEPOSIT AND DEGENERATION NEC",10015919,10077890,10077890,10077890
37351,MYCOPHENOLATE USED FOR LIVER TRANSPLANT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
37395,HER EYELID WAS STILL SWOLLEN 1 MONTH AFTER THE INCISION AND CURETTAGE SO A SUBPALPEBRAL CONJUNCTIVA TA INJECTION (2 MG/0.05 ML),Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
37396,EXPOSURE VIA BREAST MILK,Exposure via breast milk,EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080751,10080751,10080751
37417,LIVER FUNCTION TEST INCREASED,Liver function test increased,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10077692
37419,"ABNORMAL SIGNAL IN THE SUBCORTICAL OCCIPITOPARIETAL WHITE MATTER AND MORE CONFLUENT AREAS OF SIGNAL HYPERINTENSITY IN THE BIHEMISPHERIC FRONTAL REGION, THALAMUS AND CEREBELLAR HEMISPHERES",Hyperintensity in brain deep nuclei,HYPERINTENSITY IN BRAIN DEEP NUCLEI,HYPERINTENSITY IN BRAIN DEEP NUCLEI,STRUCTURAL BRAIN DISORDERS NEC,STRUCTURAL BRAIN DISORDERS,10029205,10079392,10079392,10079392
37525,MULTI ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
37533,CEFUROXIME USED FOR TREATMENT OF SEPSIS,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
37545,NORMOCYTIC ANEMIA,normocytic anemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029785,10029784,10029785
37554,CARDIAC FUNCTION DECREASED,Cardiac dysfunction,CARDIAC DYSFUNCTION,CARDIAC DYSFUNCTION,CARDIAC DISORDERS NEC,CARDIAC DISORDER SIGNS AND SYMPTOMS,10007541,10079751,10079751,10079751
37568,NORMOCYTIC ANEMIA,Normocytic anaemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029785
37589,DRUG EXPOSURE VIA LACTATION WITH NO ADVERSE EVENT,Drug exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
37595,HIV 1 PERSISTENT VIREMIA,HIV viraemia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077716,10077716,10077718
37604,INABILITY TO PERFORM DAILY CHORES,Loss of personal independence in daily activities,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10079487,10079487,10079487
37662,LIGHT MICROSCOPY REVEALED ACUTE TUBULAR INJURY,Renal tubular injury,RENAL TUBULAR INJURY,RENAL TUBULAR INJURY,RENAL VASCULAR AND ISCHAEMIC CONDITIONS,RENAL DISORDERS (EXCL NEPHROPATHIES),10038359,10078933,10078933,10078933
37734,JC VIRUS TEST POSITIVE (CSF 50000 COPY/MIC L),JC polyomavirus test positive,JC VIRUS TEST POSITIVE,JC POLYOMAVIRUS TEST POSITIVE,VIRUS IDENTIFICATION AND SEROLOGY,MICROBIOLOGY AND SEROLOGY INVESTIGATIONS,10022891,10068795,10070356,10068795
37741,HYPERSENSITIVITY MYOCARDITIS,Hypersensitivity myocarditis,HYPERSENSITIVITY MYOCARDITIS,HYPERSENSITIVITY MYOCARDITIS,NONINFECTIOUS MYOCARDITIS,MYOCARDIAL DISORDERS,10007541,10081004,10081004,10081004
37777,PARTIAL RESPONSE,Therapy partial responder,PARTIAL RESPONDER TO THERAPY,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10066429
37863,MULTIORGANFAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
37865,THE LESION DID NOT IMPROVE.,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
37887,MULTIPLE ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
37938,THE PATIENT RECEIVED LORAZEPAM WHICH IS RELATIVELY CONTRAINDICATED IN OSA,Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
37952,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
37966,MULTIPLE ORGAN FAILURE,multiple organ failure,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028237,10077361,10028237
38024,THE PATIENT DEVELOPED SUSPECTED INDUCTION OF PSYCHOTIC SYMPTOMS,Psychotic symptom,PSYCHOTIC SYMPTOM,PSYCHOTIC SYMPTOM,PSYCHOTIC DISORDER NEC,SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS,10037175,10079254,10079254,10079254
38039,MITOMYCIN C USED FOR ADVANCED UNCONTROLLED PRIMARY OPEN-ANGLE GLAUCOMA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
38158,TUMEFACTIVE DEMYELINATING LESIONS,tumefactive demyelinating lesions,TUMEFACTIVE MULTIPLE SCLEROSIS,TUMEFACTIVE MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS ACUTE AND PROGRESSIVE,DEMYELINATING DISORDERS,10029205,10078556,10078556,10078556
38169,STRONG SYMPATHETIC ACTIVATION,Paroxysmal sympathetic hyperactivity,PAROXYSMAL SYMPATHETIC HYPERACTIVITY,PAROXYSMAL SYMPATHETIC HYPERACTIVITY,AUTONOMIC NERVOUS SYSTEM DISORDERS,NEUROMUSCULAR DISORDERS,10029205,10078476,10078476,10078476
38218,TADALAFIL-ASSOCIATED RECURRENT FIXED DRUG ERUPTION FOLLOWING ITS ABUSE,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
38336,DIAGNOSED THE MEDIASTINAL TUMOR AS HAVING HISTOLOGIC AND IMMUNOHISTOCHEMICAL FEATURES OF MONOPHASIC SYNOVIAL SARCOMA.SHE WAS GIVEN TWO CYCLES OF ADJUVANT CHEMOTHERAPY USING DOCETAXEL (,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
38341,CONTACT ALLERGY TO BENZALKONIUM CHLORIDE,Allergic reaction to excipient,ALLERGIC REACTION TO EXCIPIENT,ALLERGIC REACTION TO EXCIPIENT,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10078853,10078853,10078853
38359,SEVERITY OF THE PAIN PREVENTED HER FROM MOVING INDEPENDENTLY,Activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
38393,PATIENTâ€™S NEUROLOGICAL STATUS HAD PROGRESSED DUE TO THE IMMUNE PROCESS,Neuromyelitis optica,NEUROMYELITIS OPTICA,NEUROMYELITIS OPTICA SPECTRUM DISORDER,DEMYELINATING DISORDERS NEC,DEMYELINATING DISORDERS,10029205,10029322,10077875,10029322
38405,EROSIONS OF THE PALATE AND LIPS,palate injury,PALATE INJURY,PALATE INJURY,SITE SPECIFIC INJURIES NEC,INJURIES NEC,10022117,10079812,10079812,10079812
38444,CONTRAINDICATED PRODUCT ADMINISTERED,Contraindicated product administered,CONTRAINDICATED PRODUCT ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10078504,10078504,10078504
38475,FACIAL DROOP,facial droop,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016044,10016062,10016044
38502,REFRACTORY TO THE AMIODARONE THERAPY,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
38541,PROPRANOLOL USED FOR ARRYTHMIA,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
38545,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
38568,METHOTREXATE ASSOCIATED EPSTEIN-BARR VIRUS MUCOCUTANEOUS ULCER,Epstein Barr virus positive mucocutaneous ulcer,EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER,EPSTEIN BARR VIRUS POSITIVE MUCOCUTANEOUS ULCER,LYMPHOPROLIFERATIVE DISORDERS NEC (EXCL LEUKAEMIAS AND LYMPHOMAS),HAEMATOPOIETIC NEOPLASMS (EXCL LEUKAEMIAS AND LYMPHOMAS),10029104,10079386,10079386,10079386
38599,MYCOPHENOLATE MOFETIL USED FOR TREATMENT OF CROHN'S DISEASE,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
38675,ANTERIOR TIBIAL AND DORSALIS PEDIS ARTERY OCCLUSION,Peripheral artery occlusion,TIBIAL ARTERY OCCLUSION,PERIPHERAL ARTERY OCCLUSION,"PERIPHERAL VASOCONSTRICTION, NECROSIS AND VASCULAR INSUFFICIENCY","ARTERIOSCLEROSIS, STENOSIS, VASCULAR INSUFFICIENCY AND NECROSIS",10047065,10077772,10057525,10077772
38677,DIFFUSE ESOPHAGEAL WALL THICKENING,Mucosal hypertrophy,MUCOSAL THICKENING,MUCOSAL HYPERTROPHY,MUCOSAL FINDINGS ABNORMAL,GENERAL SYSTEM DISORDERS NEC,10018065,10079674,10079674,10080991
38747,DYSMETRIA/MILD BILATERAL DYSMETRIA,dysmetria,DYSMETRIA,DYSMETRIA,COORDINATION AND BALANCE DISTURBANCES,NEUROLOGICAL DISORDERS NEC,10029205,10013936,10013936,10013936
38871,"JC VIRUS POSITIVE (6,283,000 COPIES/ML)",JC polyomavirus test positive,JC VIRUS TEST POSITIVE,JC POLYOMAVIRUS TEST POSITIVE,VIRUS IDENTIFICATION AND SEROLOGY,MICROBIOLOGY AND SEROLOGY INVESTIGATIONS,10022891,10068795,10070356,10068795
39029,OVERSEDATION,Sedation complication,OVERSEDATION,SEDATION COMPLICATION,ANAESTHETIC AND ALLIED PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10033305,10079741,10033305
39081,METRONIDAZOLE USED IN CHORIOAMNIONITIS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
39153,PULMONARY PARACOCCIDIOIDOMYCOSIS,Pulmonary paracoccidioidomycosis,PULMONARY PARACOCCIDIOIDOMYCOSIS,PULMONARY PARACOCCIDIOIDOMYCOSIS,PARACOCCIDIOIDES INFECTIONS,FUNGAL INFECTIOUS DISORDERS,10021881,10080468,10080468,10080468
39161,"USED PLEX, MIRTAZAPINE, STEROIDS, AND MARAVI-ROC. HOWEVER, SHE CONTINUED TO CLINICALLY WORSEN",Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
39162,EOSINOPHILIC PLEURAL EFFUSION,Eosinophilic pleural effusion,EOSINOPHILIC PLEURAL EFFUSION,EOSINOPHILIC PLEURAL EFFUSION,PNEUMOTHORAX AND PLEURAL EFFUSIONS NEC,PLEURAL DISORDERS,10038738,10080148,10080148,10080148
39186,EXCESSIVE SEDATION,sedation excessive,SEDATION EXCESSIVE,SEDATION COMPLICATION,ANAESTHETIC AND ALLIED PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10039898,10079741,10039898
39203,LIVER FUNCTION TEST INCREASED/FURTHER INCREASE OF LIVER FUNCTION TEST VALUES/INCREASED AMINOTRANSFERASE VALUES,Liver function test increased,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10077692,10077692,10077692
39282,PARENTAL PHYSICAL RESTRAINT TO PREVENT FURTHER INJURY. CAR RIDES AND IBUPROFEN PROVIDED,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
39292,WITHDRAWAL,Withdrawal catatonia,WITHDRAWAL CATATONIA,WITHDRAWAL CATATONIA,DECREASED PHYSICAL ACTIVITY LEVELS,CHANGES IN PHYSICAL ACTIVITY,10037175,10081010,10081010,10081010
39390,INTRAVENOUS INFUSION OF PIRACETAM/INVOLUNTARY MOVEMENT. WITH RHYTHMIC CONTRACTIONS (100 - 120/MIN,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
39487,THE PATIENT USED PROPRANOLOL HYDROCHLORIDE FOR INFANTILE HEMANGIOMAS WITH NO ADVERSE EVENT (DRUG USE FOR UNAPPROVED INDICATION),drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
39500,CHURG STRAUSS SYNDROME,Eosinophilic granulomatosis with polyangiitis,CHURG STRAUSS SYNDROME,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10009164,10078117,10009164
39503,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
39661,PATIENT WAS UNABLE TO WORK FOR ALMOST FOUR MONTHS,activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
39678,"IN BRAIN MRI, SHOWED JUST MILD GENERALIZED CORTICAL ATROPHY, MUCOSAL THICKENING WITH ENHANCEMENT AT ALL PARANASAL SINUSES",mucosal thickening,MUCOSAL THICKENING,MUCOSAL HYPERTROPHY,MUCOSAL FINDINGS ABNORMAL,GENERAL SYSTEM DISORDERS NEC,10018065,10080991,10079674,10080991
39692,"APPARENT MINERALOCORTICOID EXCESS SYNDOME SECONDARY TO HIGH-DOSE
ITRACONAZOLE",Apparent mineralocorticoid excess,APPARENT MINERALOCORTICOID EXCESS,APPARENT MINERALOCORTICOID EXCESS,ENDOCRINE DISORDERS CONGENITAL NEC,ENDOCRINE DISORDERS CONGENITAL,10010331,10080229,10080229,10080229
39705,MILD SYMPTOMS OF NORMOCYTIC ANEMIA,Normocytic anemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029785,10029784,10029785
39711,THE PATIENT WAS ADMINISTERED CYCLOPHOSPHAMIDE AND VINCRISTINE FOR LI-FRAUMENI SYNDROME (DRUG USE FOR UNAPPROVED INDICATION WITH NO ADVERSE EVENT),Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
39740,NORMOCYTIC ANAEMIA,Normocytic anaemia,NORMOCYTIC ANAEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029784
39766,MULTIPLE ORGAN FAILURE FOLLOWING VENTILATOR ASSOCIATED PNEUMONIA,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
39778,MULTI-ORGAN FAILURE,Multi-organ failure,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
39879,CARBAMAZEPINE USED FOR SUNCT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
39900,CUTANEOUS NOCARDIOSIS,cutaneous nocardiosis,CUTANEOUS NOCARDIOSIS,CUTANEOUS NOCARDIOSIS,NOCARDIA INFECTIONS,BACTERIAL INFECTIOUS DISORDERS,10021881,10080436,10080436,10080436
40005,"CONTENTS OF THE REPERFUSATE (STARCH, ALLOPURINOL, ADENOSINE AND PENICILLIN) FROM THE GRAFT LIVER",Exposure via transplant,EXPOSURE VIA TRANSPLANT,EXPOSURE VIA TRANSPLANT,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10079736,10079736,10079736
40009,GAMBLING ADDICTION,gambling addiction,GAMBLING ADDICTION,GAMBLING DISORDER,SUBSTANCE RELATED AND ADDICTIVE DISORDERS,PSYCHIATRIC DISORDERS NEC,10037175,10017656,10078070,10017656
40072,LOMUSTINE USED FOR ACUTE MYELOID LEUKEMIA,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
40094,CHRONIC PANCREATIC INSUFFICIENCY DUE TO HYPERSENSITIVITY SYNDROME REACTION,pancreatic insufficiency,PANCREATIC INSUFFICIENCY,PANCREATIC FAILURE,PANCREATIC DISORDERS NEC,EXOCRINE PANCREAS CONDITIONS,10017947,10033628,10079281,10033628
40160,SPRUE-LIKE ENTEROPATHY ASSOCIATED TO TAKING OLMESARTAN,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
40222,ACETYLSALICYLIC ACID WAS USED IN PREGNANCY-INDUCED HYPERTENSION,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
40300,CITALOPRAM USED FOR NARCOLEPSY (OFF LABEL USE),Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
40347,OLANZAPINE USED FOR DEPRESSIVE DISORDER,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
40400,MULTIPLE ORGAN DYSFUNCTION SYNDROME FOLLOWING SEPTIC SHOCK AND MULTIPLE ORGAN HEMORRHAGE,Multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
40545,PREDNISONE FOR HEART TRANSPLANT,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
40579,REACTION TO DRUG EXCIPIENT,reaction to drug excipient,REACTION TO DRUG EXCIPIENT,REACTION TO EXCIPIENT,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10037975,10079925,10037975
40606,NORMOCYTIC ANEMIA,normocytic anemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029785,10029784,10029785
40611,NON-RESPONDER TO TREATMENT,No therapeutic response ,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
40618,NO SIGNS OF RECOVERY IN THE PATIENT'S PANCYTOPENIA,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
40639,MULTIPLE ORGAN TOXICITY,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
40640,ABRUPTLY COMBATIVE AND THREATENING WITH STAFF.,Patient uncooperative,PATIENT UNCOOPERATIVE,PATIENT UNCOOPERATIVE,SOCIAL ISSUES NEC,LIFESTYLE ISSUES,10041244,10077706,10077706,10077706
40671,DISCONTINUED THE MEDICATION AFTER 14 DAYS,intentional dose omission,INTENTIONAL DOSE OMISSION,INTENTIONAL DOSE OMISSION,INTENTIONAL PRODUCT USE ISSUES,OFF LABEL USES AND INTENTIONAL PRODUCT MISUSES/USE ISSUES,10022117,10079221,10079221,10079221
40762,IRREGULAR DEFECTION,Defecation disorder,DEFECATION DISORDER,DEFAECATION DISORDER,GASTROINTESTINAL DYSKINETIC DISORDERS,GASTROINTESTINAL MOTILITY AND DEFAECATION CONDITIONS,10017947,10079939,10079938,10079939
40763,HYPOMIMIA,Reduced facial expression,REDUCED FACIAL EXPRESSION,REDUCED FACIAL EXPRESSION,PARKINSON'S DISEASE AND PARKINSONISM,MOVEMENT DISORDERS (INCL PARKINSONISM),10029205,10078576,10078576,10078576
40830,CONTRAINDICATED DRUG ADMINISTERED,Contraindicated drug administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
40891,REFRACTORY GRAFT VERSUS HOST DISEASE (NO THERAPEUTIC RESPONSE),No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
40901,EDEMA AND ERYTHEMA OF THE LARGE LIPS,Lip erythema,LIP ERYTHEMA,LIP ERYTHEMA,ORAL SOFT TISSUE SIGNS AND SYMPTOMS,ORAL SOFT TISSUE CONDITIONS,10017947,10080124,10080124,10080124
41005,PARTIAL VIROLOGICAL RESPONSE (38IU/ML),Therapy partial responder,THERAPY PARTIAL RESPONDER,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10078115
41138,"RITUXIMAB,CICLOSPORIN AND PREDNISONE USED FOR CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)",Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
41207,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
41209,VALPROATE USED FOR SCHIZOPHRENIA,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
41269,DROOPING ON THE RIGHT SIDE OF HIS MOUTH,Facial paralysis,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016044
41323,"MODERATE DEFICIT IN EXECUTIVE FUNCTIONS, VISUOSPATIAL ABILITY",Visuospatial deficit,VISUOSPATIAL DEFICIT,VISUOSPATIAL DEFICIT,CORTICAL DYSFUNCTION NEC,NEUROLOGICAL DISORDERS NEC,10029205,10080880,10080880,10080880
41338,TAKING ABILIFY MAINTENA FOR SCHIZOAFFECTIVE DISORDER,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
41344,OLMESARTAN INDUCED SPRUE LIKE ENTEROPATHY,Sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
41367,AMS,Hypobarism,ACUTE MOUNTAIN SICKNESS,HYPOBARISM,ATMOSPHERIC PRESSURE INJURIES,INJURIES BY PHYSICAL AGENTS,10022117,10028013,10077606,10000876
41450,RITUXIMAB AND BORTEZOMIB USED AS INDUCTION THERAPY FOR KIDNEY TRANSPLANT,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
41451,"PATIENT SHOWED MINIMAL IMPROVEMENT WITH METHYLPREDNISOLONE, IMMUNOGLOBULIN AND PLASMAPHERESIS",partial response,PARTIAL RESPONDER TO THERAPY,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10066429,10078115,10066429
41458,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
41464,"AORTIC, MITRAL, TRICUSPID VALVES THICKENING",Cardiac valve thickening,CARDIAC VALVE THICKENING,CARDIAC VALVE THICKENING,CARDIAC VALVE DISORDERS NEC,CARDIAC VALVE DISORDERS,10007541,10079587,10079587,10079587
41469,NONKETOTIC HYPERGLYCINEMIA,nonketotic hyperglycinaemia,NONKETOTIC HYPERGLYCINAEMIA,HYPERGLYCINAEMIA,INBORN ERRORS OF AMINO ACID METABOLISM,METABOLIC AND NUTRITIONAL DISORDERS CONGENITAL,10010331,10070639,10080883,10070639
41485,ALLERGY ON PRODUCTS EXCIPIENT / THE HYPERSENSITIVITY TO COW MILK PROTEINS AND THE LACTOSE CONTAINED IN THE MEDICINES/ALLERGIC REACTION TO DRUG EXCIPIENT,Allergic reaction to drug excipient,ALLERGIC REACTION TO DRUG EXCIPIENT,ALLERGIC REACTION TO EXCIPIENT,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10079923,10078853,10079923
41508,PATIENT RECEIVED RAMIPRIL FOR DIABETES,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
41550,NIMODIPINE USED FOR REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME,Drug use for unapproved indication ,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
41633,HIV VIREMIA,HIV viremia,HIV VIREMIA,HIV VIRAEMIA,RETROVIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10077718,10077716,10077718
41674,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
41681,ALLERGIC REACTION TO EXCIPIENT,Allergic reaction to excipient,ALLERGIC REACTION TO EXCIPIENT,ALLERGIC REACTION TO EXCIPIENT,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10078853,10078853,10078853
41853,TRANSITORY APHASIA,Transient aphasia,TRANSIENT APHASIA,TRANSIENT APHASIA,TRANSIENT CEREBROVASCULAR EVENTS,CENTRAL NERVOUS SYSTEM VASCULAR DISORDERS,10029205,10080106,10080106,10080106
41871,INTRABDOMINAL COLLECTION (GRADE IIIA),Intra-abdominal fluid collection,INTRA-ABDOMINAL FLUID COLLECTION,INTRA-ABDOMINAL FLUID COLLECTION,PERITONEAL AND RETROPERITONEAL DISORDERS,PERITONEAL AND RETROPERITONEAL CONDITIONS,10017947,10078659,10078659,10078659
41874,COMPLICATED BY SECONDARY BACTERIAL INFECTION TREATMENT WITH TRIAMCINOLONE 0.1% OINTMENT HAD LITTLE EFFECT,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
41875,MULTI ORGAN FAILURE,multi organ failure,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028151,10077361,10028151
41883,OESOPHAGEAL SUBMUCOSAL HAEMATOMA,Oesophageal intramural haematoma,OESOPHAGEAL INTRAMURAL HAEMATOMA,OESOPHAGEAL INTRAMURAL HAEMATOMA,GASTRIC AND OESOPHAGEAL HAEMORRHAGES,GASTROINTESTINAL HAEMORRHAGES NEC,10017947,10077486,10077486,10077486
41906,STOOL INCONTINENCE,Fecal incontinence,FECAL INCONTINENCE,ANAL INCONTINENCE,GASTROINTESTINAL SIGNS AND SYMPTOMS NEC,GASTROINTESTINAL SIGNS AND SYMPTOMS,10017947,10016296,10077605,10016296
41909,RIGHT FACIAL DROOP,Facial paralysis,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016062,10016062,10016044
42000,PATERNAL EXPOSURE BEFORE PREGNANCY,Paternal exposure before pregnancy,PATERNAL EXPOSURE BEFORE PREGNANCY,PATERNAL EXPOSURE BEFORE PREGNANCY,"EXPOSURES ASSOCIATED WITH PREGNANCY, DELIVERY AND LACTATION","EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080093,10080093,10080093
42035,RITUXIMAB USED FOR AMR AND TRANSPLANT GLOMERULOPATHY,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
42044,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
42083,ANKLE BRACHIAL INDEX ABNORMAL,Ankle brachial index abnormal,ANKLE BRACHIAL INDEX ABNORMAL,ANKLE BRACHIAL INDEX ABNORMAL,VASCULAR TESTS NEC (INCL BLOOD PRESSURE),CARDIAC AND VASCULAR INVESTIGATIONS (EXCL ENZYME TESTS),10022891,10077378,10077378,10077378
42097,FACIAL DROOP,facial droop,FACIAL DROOP,FACIAL PARALYSIS,FACIAL CRANIAL NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10016044,10016062,10016044
42162,SERIAL MRIS SHOWED ACTIVE TUMEFACTIVE MS WITH ALMOST ENTIRE BRAINSTEM INVOLVEMENT AS WELL AS LARGE HEMISPHERIC TUMEFACTIVE LESIONS/VERY SEVERE MULTIFOCAL REBOUND RELAPSE,Tumefactive multiple sclerosis,TUMEFACTIVE MULTIPLE SCLEROSIS,TUMEFACTIVE MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS ACUTE AND PROGRESSIVE,DEMYELINATING DISORDERS,10029205,10078556,10078556,10078556
42226,MULTIORGAN FAILURE,Multiple organ dysfunction syndrome,MULTIORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028162
42237,SEVERE MULTIPLE ORGAN DYSFUNCTION SYNDROME,severe multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
42245,CARDIAC VALVE THICKENING,cardiac valve thickening,CARDIAC VALVE THICKENING,CARDIAC VALVE THICKENING,CARDIAC VALVE DISORDERS NEC,CARDIAC VALVE DISORDERS,10007541,10079587,10079587,10079587
42268,DEPRESSED MOOD AND GAMBLING TENDENCIES/ PATHOLOGICAL GAMBLING,Gambling disorder,PATHOLOGICAL GAMBLING,GAMBLING DISORDER,SUBSTANCE RELATED AND ADDICTIVE DISORDERS,PSYCHIATRIC DISORDERS NEC,10037175,10034158,10078070,10034158
42269,DISSEMINATED PENICILLIUM MARNEFFEI INFECTION,Penicillium infection,PENICILLIUM INFECTION,PENICILLIUM INFECTION,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10078580,10078580,10078580
42293,RELAPSE OF BIPOLAR DISORDER AFTER SWITCH OF ORAL ARIPIPRAZOLE TO IM DEPOT,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
42475,EXCESSIVE DAYTIME SLEEPINESS IN THE MORNING,Sedation complication,SEDATION EXCESSIVE,SEDATION COMPLICATION,ANAESTHETIC AND ALLIED PROCEDURAL COMPLICATIONS,PROCEDURAL RELATED INJURIES AND COMPLICATIONS NEC,10022117,10056213,10079741,10039898
42510,SUBSTITUTION ERROR WITH HYOSCINE HYDROBROMIDE,Product substitution error,PRODUCT SUBSTITUTION ERROR,PRODUCT SUBSTITUTION ERROR,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10078984,10078984,10078984
42521,STRONG JCV POSITIVITY,JC virus test positive,JC VIRUS TEST POSITIVE,JC POLYOMAVIRUS TEST POSITIVE,VIRUS IDENTIFICATION AND SEROLOGY,MICROBIOLOGY AND SEROLOGY INVESTIGATIONS,10022891,10068795,10070356,10068795
42587,NIFEDIPINE GIVEN FOR PREMATURE PRELABOR RUPTURE OF MEMBRANES,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
42655,FENTANYL USE FOR PELVIC PAIN DUE TO INTERSTITIAL CYSTITIS,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
42771,CEFTRIAXONE-INDUCED PSEUDOLITHIASIS FOLLOWING OFF LABEL USE OF DRUG,Pseudocholelithiasis,PSEUDOCHOLELITHIASIS,PSEUDOCHOLELITHIASIS,CHOLECYSTITIS AND CHOLELITHIASIS,GALLBLADDER DISORDERS,10019805,10066884,10066884,10066884
42793,INABILITY TO WALK,Gait inability,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10017581,10017581,10049278
42812,MOF,Multiple organ dysfunction syndrome,MULTIPLE ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028237
42817,TINNITUS,Auditory disorder,AUDITORY DISORDER,AUDITORY DISORDER,HEARING DISORDERS NEC,HEARING DISORDERS,10013993,10003778,10003778,10003778
42870,ABSENCE OF B-CELLS IN PERIPHERAL BLOOD CONSIDERED TO BE SECONDARY TO RITUXIMAB TREATMENT,absence of B-cells in peripheral blood considered to be secondary to rituximab treatment,B-CELL APLASIA,B-CELL APLASIA,LEUKOPENIAS NEC,WHITE BLOOD CELL DISORDERS,10005329,10080721,10080721,10080721
42904,UNABLE TO WALK AND PRESENTED IN A WHEELCHAIR,Unable to walk,UNABLE TO WALK,GAIT INABILITY,GAIT DISTURBANCES,GENERAL SYSTEM DISORDERS NEC,10018065,10049278,10017581,10049278
42984,RECURRENCE OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS AFTER WEANING OFF DOSES OF PREDNISONE,Eosinophilic granulomatosis with polyangiitis,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,VASCULITIDES,IMMUNE DISORDERS NEC,10021428,10078117,10078117,10078117
43095,RELAPSE AMONG NEUROMYELITIS OPTICA SPECTRUM DISORDER,neuromyelitis optica,NEUROMYELITIS OPTICA,NEUROMYELITIS OPTICA SPECTRUM DISORDER,DEMYELINATING DISORDERS NEC,DEMYELINATING DISORDERS,10029205,10029322,10077875,10029322
43138,RENAL TUBULAR DYSFUNCTION,Renal tubular dysfunction,RENAL TUBULAR DYSFUNCTION,RENAL TUBULAR DYSFUNCTION,NEPHROPATHIES AND TUBULAR DISORDERS NEC,NEPHROPATHIES,10038359,10050335,10050335,10050335
43148,AMOXICILLIN WITH CLAVULANIC ACID USED FOR CHILBLAINS,Product use in unapproved indication,PRODUCT USE IN UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10076476,10076476,10076476
43219,A SPECTACULAR RESPONSE TO TREATMENT WITH ORAL PENTOXIFYLLINE FORINTRALYMPHATIC HISTIOCYTOSIS,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
43233,PARTIAL RESPONSE,Therapy partial responder,THERAPY PARTIAL RESPONDER,THERAPY PARTIAL RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10078115,10078115,10078115
43400,DRUG USE FOR UNAPPROVED INDICATION,Product use in unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
43431,ANKLE BRACHIAL INDEX ABNORMAL,Ankle brachial index abnormal,ANKLE BRACHIAL INDEX ABNORMAL,ANKLE BRACHIAL INDEX ABNORMAL,VASCULAR TESTS NEC (INCL BLOOD PRESSURE),CARDIAC AND VASCULAR INVESTIGATIONS (EXCL ENZYME TESTS),10022891,10077378,10077378,10077378
43505,RELAPSE OF ADULT STILL'S DISEASE FOLLOWING LACK OF DRUG EFFECT,Still's disease,ADULT ONSET STILL'S DISEASE,STILL'S DISEASE,RHEUMATOID ARTHROPATHIES,JOINT DISORDERS,10028395,10079456,10042061,10079456
43534,EPLERENONE IN THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY,drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
43643,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
43706,DRUG EXPOSURE VIA LACTATION WITH NO ADR,exposure via breast milk,EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10080751,10080751,10080751
43835,WITHOUT ANY SYMPTOM REMISSION,No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
43839,NO THERAPEUTIC RESPONSE,Therapy non-responder,THERAPY NON-RESPONDER,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10051082,10051082,10051082
43935,MULTI ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028151
43944,HYDROXYCHLOROQUINE SULFATE USED FOR TREATMENT OF PULMONARY HEMOSIDEROSIS (OFF LABEL USE) WITH NO ADVERSE EVENT,hydroxychloroquine sulfate used for treatment of pulmonary hemosiderosis (off label use) with no adverse event,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
43964,ELEVATED LIVER TESTS,Liver function tests raised,LIVER FUNCTION TESTS RAISED,LIVER FUNCTION TEST INCREASED,LIVER FUNCTION ANALYSES,HEPATOBILIARY INVESTIGATIONS,10022891,10048556,10077692,10048556
44023,PSEUDOTUMOR CEREBRI DUE TO TAKING MINOCYCLINE,Idiopathic intracranial hypertension,PSEUDOTUMOR CEREBRI,IDIOPATHIC INTRACRANIAL HYPERTENSION,INCREASED INTRACRANIAL PRESSURE DISORDERS,INCREASED INTRACRANIAL PRESSURE AND HYDROCEPHALUS,10029205,10073807,10078904,10037149
44055,"MALE PATIENT RECEIVED ZOPICLONE AND LORAZEPAM, WHICH WERE CONTRAINDICATED",Contraindicated product administered,CONTRAINDICATED DRUG ADMINISTERED,CONTRAINDICATED PRODUCT ADMINISTERED,PRODUCT ADMINISTRATION ERRORS AND ISSUES,MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10074899,10078504,10074899
44057,MULTIPLE ORGAN DYSFUNCTION SYNDROME,Multiple organ dysfunction syndrome,MULTIPLE ORGAN DYSFUNCTION SYNDROME,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10077361,10077361,10077361
44151,RECURRENT LARYNGEAL NERVE PALSY,Paralysis recurrent laryngeal nerve,PARALYSIS RECURRENT LARYNGEAL NERVE,PARALYSIS RECURRENT LARYNGEAL NERVE,VAGUS NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10033830,10033830,10033830
44258,DILATED LEFT VENTRICLE WITH SEVERE SYSTOLIC IMPAIRMENT,Left ventricular dilatation,LEFT VENTRICULAR DILATATION,LEFT VENTRICULAR DILATATION,MYOCARDIAL DISORDERS NEC,MYOCARDIAL DISORDERS,10007541,10050043,10050043,10050043
44315,HEPATITIS B REACTIVATION,Hepatitis B reactivation,HEPATITIS B REACTIVATION,HEPATITIS B REACTIVATION,HEPATITIS VIRAL INFECTIONS,VIRAL INFECTIOUS DISORDERS,10021881,10058827,10058827,10058827
44322,NO RESPONSE,NO THERAPEUTIC RESPONSE,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
44339,SYSTEMIC HYPERSENSITIVITY REACTION WITH SEVERE HEPATOTOXICITY/CROSS-REACTIVE HYPERSENSITIVITY,Cross reactive drug hypersensitivity,CROSS REACTIVE DRUG HYPERSENSITIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10057384,10079645,10057384
44382,ADVANCED EMPD THAT WERE SUCCESSFULLY CONTROLLED BY DOCETAXEL WITH CISPLATIN,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
44457,SCOPULARIOPSIS BREVICAULIS,Scopulariopsis infection,SCOPULARIOPSIS INFECTION,SCOPULARIOPSIS INFECTION,FUNGAL INFECTIONS NEC,FUNGAL INFECTIOUS DISORDERS,10021881,10079529,10079529,10079529
44486,MULTI-ORGAN FAILURE,Multiple organ dysfunction syndrome,MULTI-ORGAN FAILURE,MULTIPLE ORGAN DYSFUNCTION SYNDROME,GENERAL SIGNS AND SYMPTOMS NEC,GENERAL SYSTEM DISORDERS NEC,10018065,10028154,10077361,10028154
44534,ACETYL SALICYLIC ACID IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES IN PATIENT WITH A BLEEDING,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
44576,FIXED DRUG ERUPTION,Fixed eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
44693,COMPROMISED FUNCTION FOR ACTIVITIES OF DAILY LIVING,Activities of daily living impaired,ACTIVITIES OF DAILY LIVING IMPAIRED,LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES,DISABILITY ISSUES,LIFESTYLE ISSUES,10041244,10050954,10079487,10050954
44732,RIFAMPICIN USE FOR ACUTE STAPHYLOCOCCAL PROSTHETIC JOINT INFECTION,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
44766,ARTERIAL THROMBOSIS,Therapy non-responder,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
44822,LOSS OF AMPLITUDE OF MOTOR EVOKED POTENTIALS,Transcranial electrical motor evoked potential monitoring abnormal,TRANSCRANIAL ELECTRICAL MOTOR EVOKED POTENTIAL MONITORING ABNORMAL,TRANSCRANIAL ELECTRICAL MOTOR EVOKED POTENTIAL MONITORING ABNORMAL,NEUROLOGIC DIAGNOSTIC PROCEDURES,"NEUROLOGICAL, SPECIAL SENSES AND PSYCHIATRIC INVESTIGATIONS",10022891,10077470,10077470,10077470
44895,MULTIFOCAL FIXED DRUG ERUPTION,fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
44949,THE CH GRADUALLY DECREASED IN SIZE BUT STILL REMAINS,Drug effective for unapproved indication,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,DRUG EFFECTIVE FOR UNAPPROVED INDICATION,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10079317,10079317,10079317
44974,LOSS OF MAJOR MOLECULAR RESPONSE (MMR),No therapeutic response,NO THERAPEUTIC RESPONSE,THERAPY NON-RESPONDER,THERAPEUTIC AND NONTHERAPEUTIC RESPONSES,THERAPEUTIC AND NONTHERAPEUTIC EFFECTS (EXCL TOXICITY),10018065,10063670,10051082,10063670
45005,MULTIFOCAL FIXED DRUG ERUPTION,Fixed drug eruption,FIXED DRUG ERUPTION,FIXED ERUPTION,DERMATITIS ASCRIBED TO SPECIFIC AGENT,EPIDERMAL AND DERMAL CONDITIONS,10040785,10016740,10016741,10016740
45059,RUXOLITINIB AND PREDNISONE USED IN CORTICOSTEROID REFRACTORY GRAFT VERSUS HOST DISEASE,Drug use for unapproved indication,DRUG USE FOR UNAPPROVED INDICATION,PRODUCT USE IN UNAPPROVED INDICATION,"MEDICATION ERRORS, PRODUCT USE ERRORS AND ISSUES NEC",MEDICATION ERRORS AND OTHER PRODUCT USE ERRORS AND ISSUES,10022117,10053746,10076476,10053746
45100,BENZODIAZEPINES MIGHT CROSS-REACT/CROSS-REACT/ CROSSREACTING MOLECULES,Cross reactive drug hypersensitivity,CROSS REACTIVE DRUG HYPERSENSITIVITY,THERAPEUTIC PRODUCT CROSS-REACTIVITY,"ALLERGIES TO FOODS, FOOD ADDITIVES, DRUGS AND OTHER CHEMICALS",ALLERGIC CONDITIONS,10021428,10057384,10079645,10057384
45139,SPRUE-LIKE ENTEROPATHY ASSOCIATED WITH VALSARTAN,sprue-like enteropathy,SPRUE-LIKE ENTEROPATHY,SPRUE-LIKE ENTEROPATHY,MALABSORPTION SYNDROMES,MALABSORPTION CONDITIONS,10017947,10079622,10079622,10079622
45191,NORMOCYTIC ANEMIA,Normocytic anaemia,NORMOCYTIC ANEMIA,NORMOCYTIC ANAEMIA,ANAEMIAS NEC,ANAEMIAS NONHAEMOLYTIC AND MARROW DEPRESSION,10005329,10029784,10029784,10029785
45203,RECURRENT LARYNGEAL NERVE PALSY,Paralysis recurrent laryngeal nerve,RECURRENT LARYNGEAL NERVE PALSY,PARALYSIS RECURRENT LARYNGEAL NERVE,VAGUS NERVE DISORDERS,CRANIAL NERVE DISORDERS (EXCL NEOPLASMS),10029205,10033830,10033830,10038130
45281,LACTATION WAS CONTINUED UNDER ANTIVIRAL THERAPY (DRUG EXPOSURE VIA BREAST MILK) WITH NO ADR,Exposure via breast milk,DRUG EXPOSURE VIA BREAST MILK,EXPOSURE VIA BREAST MILK,PATHWAYS AND SOURCES OF EXPOSURE,"EXPOSURES, CHEMICAL INJURIES AND POISONING",10022117,10051075,10080751,10051075
